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Acute otitis media (OM) is the leading indication for pediatric antibiotic prescriptions, 
accounting for 25%. While the use of topical ear drops can minimize antibiotic dose and adverse 
systemic effects compared to oral antibiotics, their use has limitations due to low patient 
compliance, high dosing frequency, and difficulty of administration. Improper treatment can lead 
to chronic OM and may require surgical intervention. Previous studies have shown that gel-based 
otic delivery is possible with invasive intratympanic injection or chemical permeation enhancers 
which have demonstrated toxicity effects. Further, infection or trauma can cause tympanic 
membrane (TM) perforation, which can be chronic in up to 46% of cases. Even healing 
perforations may require months for complete closure, increasing susceptibility to infection, 
hearing loss, and other side effects. Current treatment standards include surgical grafting, which 
may result in similar detrimental side effects. Research has accordingly focused on alternative 
grafts and growth factor or stem cell therapy, which come with logistical and regulatory hurdles. 
A novel method of delivering therapeutics to the TM and middle ear was developed using 
a topical, thermoresponsive gel depot containing antibiotics or stem cell conditioned media (CM)-
loaded polymer microspheres. Results indicate that the noninvasive, sustained presentation can 
allow therapeutically relevant drug concentrations to penetrate the TM to the middle ear for up to 
14 days from one topical administration. Auditory brainstem recordings indicate that complete 
coverage of the TM is achieved and administration can be scaled up if needed. Biocompatibility 
of all materials is indicated by cytotoxicity testing as well as increased wound healing in CM and 
 v 
CM MS-treated in vitro scratch wound proliferation assays. Despite some variability in the models, 
in vivo data suggest the system may treat bacterial infection and tympanic membrane perforation, 
with future studies investigating further scaled up release and longitudinal safety testing. To our 
knowledge, this dissertation represents the first truly topical drug delivery system to the middle 
ear for OM with intact TM without the use of CPEs and topical delivery of stem cell secretome to 
the TM for chronic perforation healing. 
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1.0 Introduction and Specific Aims 
1.1 Controlled Drug Delivery 
Controlled drug delivery as a field originated in the 1960s and evolved over the decades to 
become a field of great interest and commercial and clinical success in the 21st century [1,2]. Drug 
delivery systems are beneficial due to ability to control the route of administration and dosage 
based on therapeutic need and properties of the drug itself [2]. Most of the first drug delivery 
systems were oral or transdermal delivery systems, formulated for constant zero-order release 
kinetics [1–3]. However, zero-order kinetics did not necessarily translate to constant plasma drug 
concentration, particularly from oral delivery systems, due to drug metabolism and absorption, 
resulting in a large peak followed by a decrease, rather than a maintenance of drug levels between 
minimum effective concentration and maximum concentration to prevent toxicity. Further, a zero-
order release is not ideal for all drug types or relevant for most effective therapy of all conditions 
[3]. Oral delivery systems are also limited by lack of site-specific targeting and poor blood 
circulation times [4].  
Accordingly, research became more focused on more localized or targeted drug delivery 
systems optimized for the therapeutic needs of the specific drug and condition [1,5]. Ocular and 
transdermal drug delivery systems are often targeted for development of non-invasive systems; 
however, a number of implantable or injectable drug delivery systems have been developed, 
including several implantable devices developed for female contraceptive use [1,6]. Controlled 
drug delivery systems have also shown promise in the field of tissue engineering, with scaffolds 
and other delivery systems releasing growth factors and other signaling molecules [7,8]. 
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1.1.1 Otic Biomaterials 
In addition to aforementioned ocular and transdermal use, biomaterials have a rich history 
of use in the ear, perhaps most notably the use of cochlear implants. Recent research into 
improvement of cochlear implants has focused on coatings to improve electrode function by 
locally releasing dexamethasone to prevent fibrous encapsulation and neurotrophic factors to 
preserve neurons and encourage neuronal regeneration [8]. One recent study has also investigated 
the use of 3-D printed microneedle arrays (MNAs) for delivery of therapeutics through the round 
window membrane to the cochlea [9]. Drug-eluting stents have long been used for cardiovascular 
applications and can be adapted for otolaryngology, in particular for use in the Eustachian tube, 
stenosis of which can be a cause of chronic otitis media [8,10–12]. Recent research has 
increasingly focused on drug targeting and local use of biodegradable microparticles and 
nanoparticles for drug delivery and tissue engineering in otolaryngology [7,8]. 
1.1.2 Microspheres for Controlled Drug Delivery 
Biodegradable polymer microspheres are an attractive method of providing controlled, 
localized drug release and have been investigated for a variety of applications. Drug release from 
microspheres occurs via biphasic or triphasic release with the primary phases being: 1) initial burst 
release, 2) lag phase, and 3) final phase [6,13,14]. Biphasic and triphasic release differ in that 
biphasic release does not include a lag phase [14]. Initial burst often occurs due to drug physically 
adhered to the surface of the microsphere or porosity of the matrix resulting in a fraction of the 
drug to diffuse out of the microspheres quickly [6]. The lag phase is primarily governed by no 
release or slow diffusion-based release in which drug diffuses slowly out of the polymer matrix 
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due to slow or no degradation/erosion. The final phase is governed by degradation/erosion of the 
polymer matrix resulting in greater and continuous drug release. An example of these phases can 
be seen in Figure 1. 
 
 
Figure 1: Biphasic vs. triphasic release profiles. Biphasic release is characterized by an initial burst followed by 
continuous release governed by polymer matrix degradation. Triphasic release is characterized by an initial burst, 
lag phase governed by little to no degradation resulting in no release or slow diffusion-based drug release, and a 
final continuous release phase governed by poymer degradation. These phases have different characteristics 
(percentage of cumulative drug release, percentage of release duration, etc) dependent on the properties of the 
individual controlled release system. 
 
Microspheres can be tuned to provide a variety of release profiles by adjusting polymer 
molecular weight, copolymer ratios, matrix porosity, microsphere size, and drug concentration and 
dispersion in the polymer matrix [13–17]. Release profiles can also be tuned by adjusting 
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based techniques, including oil-in-oil (O/O) or oil-in-water (O/W) single emulsions and water-in-
oil-in-water (W/O/W) or solid-in-oil-in-water (S/O/W) double emulsion fabrication [17–20]. For 
commercial scaling purposes, other fabrication methods such as spray drying can be employed 
[20]. In particular, W/O/W fabrication is amenable to encapsulation of water-soluble drugs and 
will be described further for encapsulation of relevant therapeutics in this dissertation. 
In this fabrication method, drug is dissolved in water and the aqueous drug solution is 
added to a solution of polymer dissolved in organic solvent (Figure 2). These solutions are stirred 
vigorously, usually via sonication or homogenization, to create the first water-in-oil emulsion. This 
emulsion is added to a solution of water and surfactant to stabilize the emulsion and stirred 
vigorously again to create the second W/O/W solution. The organic solvent is removed by 
evaporation while continuously stirring the emulsion and precipitated microspheres are washed to 
remove any excess reagents and dried to prevent hydrolysis during storage [20]. Fabrication 
parameters that can influence drug encapsulation and subsequent release profile include the choice 
of organic solvent and stirring rate of sonication/homogenization which affect drug encapsulation 
efficiency and size of resulting microspheres [13,20]. Therefore, if optimal release profile 
(magnitude, duration, etc) is not achieved for the target application, these parameters can be 
adjusted to tune the release profile, in addition to previously mentioned factors including choice 





Figure 2: Double emulsion water-in-oil-in-water (W/O/W) microsphere fabrication method. Aqueous drug in 
water is added to poly(lactic-co-glycolic acid) dissolved in organic solvent and sonicated to create the first water-in-
oil emulsion. This emulsion is transferred to a solution of water and surfactant and homogenized to created the 
second W/O/W emulsion. The organic solvent is allowed to evaporate before the microspheres are washed and 
freeze dried. 
 
1.1.3 Poly(lactic-co-glycolic acid) in Biomedical Applications 
A polymer frequently used in biomedical applications, particularly microsphere-based 
controlled release systems, is poly(lactic-co-glycolic acid) (PLGA) [6,14,15,20,21].  PLGA has a 
long track record of clinical use and approval by regulatory authorities including the United States 
Food and Drug Administration as it is biodegradable and its degradation products, lactic acid and 
glycolic acid, are biocompatible and easily cleared from the body [14,15,20,22,23]. 
Biodegradation is beneficial as it eliminates the need for a potentially invasive procedure to remove 
the delivery system [21]. Because of its widespread use, PLGA is widely commercially available 
in a variety of properties include molecular weights and copolymer ratios, increasing ease of use 
for further research into PLGA-based delivery systems [14,21]. Further, PLGA is extremely well 
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characterized and a number of mathematical models exist for determining release profiles of 
various therapeutics from PLGA-based delivery systems, including microsphere-based 
applications [13–15,20,24].  
1.1.4 Responsive Polymer Gels for Controlled Drug Delivery 
In recent years, a growing number of studies have also focused on gel-based drug delivery 
systems. “Smart” responsive polymers can be designed to respond to physiological and/or external 
triggers, including temperature, pH, glucose levels, ionic concentration, and ultra-violet irradiation 
[3,25–28]. These smart polymers or hydrogels are networks of polymers that can take up large 
amounts of water and be formed into particles, films, coatings, etc, and are therefore commonly 
used in a wide variety of biomedical applications [4,25,27,29]. Gels are similar but are consistent 
of a larger solid compared to liquid component [27]. One of the first uses for hydrogels in medicine 
was the advent of contact lenses in the 1960s, which are still in widespread use today [25,27]. 
Since then, a number of gel and hydrogel formulations have been developed for tissue engineering, 
diagnostics, drug delivery, and other applications [25,29]. 
Thermoresponsive hydrogels and gels in particular are useful for biomedical applications 
due to ability to be injected as a liquid and solidify in situ [30–32]. Thermoresponsive gels have 
either a lower critical solution temperature (LCST) or upper critical solution temperature (UCST), 
with LCST-driven gelation more relevant to in situ gelation for most biomedical applications. 
Below its LCST, a gel exists in a hydrophilic, water-swollen state and becomes hydrophobic above 
its LCST, expelling its water content and solidifying [25,28,33,34].  
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1.1.5 Poly(N-isopropylacrylamide) in Biomedical Applications 
In addition to a variety of natural and synthetic polymers, poly(N-isopropylacrylamide) 
(pNIPAAm) is often used in biomedical applications as a thermoresponsive gel matrix [28,32]. 
Poly(N-isopropylacrylamide) is attractive for biomedical applications due to a lower critical 
solution temperature (LCST) of approximately 32-33°C, which falls between room temperature 
and human physiological temperature of 37°C [28,31,32]. Because pNIPAAm is reverse 
thermoresponsive, it can return to a swollen state when temperature is lowered below LCST. These 
properties are beneficial for injectable and topical administration for localized drug delivery, 
allowing the gel to be injected or applied as a liquid and solidifying in situ [6,29,30]. However, 
pNIPAAm hydrogels can have poor mechanical properties and relatively fast diffusion-based 
release [30,34–36]. Addition of copolymers or crosslinkers of varying hydrophobicity or 
hydrophilicity, can influence mechanical properties and LCST of the gel, including the addition of 
poly(ethylene glycol) (PEG) which is hydrophilic and can increase LCST as well as increase speed 
of rehydration upon reverse transition [26,32,34–36]. Gels made using pNIPAAm are usually 
fabricated using free radical polymerization and can result in some toxicity, however gel 
concentrations used in biomedical applications have generally shown to be nontoxic due to high 
water content [26,27,30,35,37]. 
While controlled drug delivery can be achieved by gel-based or microsphere-based drug 
delivery systems alone, microspheres have been incorporated into gel-based systems to add a level 
of further control to the drug release and gels have been incorporated into microsphere-based 
systems as a carrier/retention mechanism for increased ease of use for injectable and topical 
applications [6,15,27,36,38]. 
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1.2 Acute Otitis Media 
1.2.1 Incidence and Severity of Otitis Media 
Acute otitis media (AOM), characterized by middle ear inflammation, acute onset, and 
duration of illness ranging from several days to two weeks, accounts for 20 million pediatrician 
visits annually and is the main indication for pediatric antibiotic prescription in the United States 
[39–42]. In fact, over 25% of antibiotic prescription is for the sole purpose of treating AOM 
[40,41]. Approximately 80% of children under three years old experience AOM at least 
once[40,41] and 30-40% of children experience at least six instances of AOM before the age of 
seven [36,37]. Recurrent AOM can develop into chronic otitis media, which often requires surgical 
intervention such as myringotomy and placement of tympanostomy tubes for ventilation and 
drainage [12,45,46]. Chronic otitis media has also been associated with sensorineural hearing loss, 
which may lead to speech and learning deficits [46–50]. In the US alone, 500,000 children undergo 
tympanostomy surgery annually at a cost of $5 billion [51]. Developing countries see over 10 times 
more incidence of OM than the US and European nations [12,47,52]. 
 
 
1.2.2 Current Clinical Standards and Associated Shortcomings 
 
Oral antibiotics remain the standard of care, although such treatment is recognized as 
impractical due to the risks of systemic side effects and antibiotic resistance associated with 
persistent biofilm formation [10,41,42,53,54]. Further, oral antibiotics may not provide adequate 
drug concentration to the middle ear to clear these persistent biofilms [55,56].  
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Though less frequently prescribed for AOM, and only in cases of non-intact TM due to 
perforation or placement of ventilation tubes, topical ear drops are also problematic, with less than 
10% of the applied drug reaching the middle ear [57]. For example, 0.2% ciprofloxacin is, if 
applied correctly to non-intact TM, delivered in quantities of 1mg/day [58]. The minimum 
inhibitory concentration (MIC) of ciprofloxacin to inhibit microorganisms commonly responsible 
for OM, including Streptococcus pneumoniae and Haemophilus influenzae [10], has been 
determined to be up to 1-2µg/mL [59,60]. With proper instillation, the standard topical antibiotic 
drop treatment [58] delivers up to 1000 times excess antibiotic to the middle ear and surrounding 
tissues, which can contribute to local and systemic side effects much like their oral counterparts 
[61]. Further limitations of standard topical ear drops include low patient compliance, particularly 
when self-medicating and for treatment durations greater than one week, associated with high 
dosing frequency and difficulty of administration [62–64]. An ideal controlled release system 
should be simple to use and deliver to the middle ear an antibiotic dose closer to the target MIC at 
a frequency that is manageable by patients and/or their caregivers. 
 
1.2.3 Sustained and Controlled Drug Delivery for Otitis Media Treatment 
Accordingly, research has focused on expanding and improving topical antibiotic treatment 
to address the aforementioned shortcomings. Studies by Otonomy, Inc. have shown success in 
releasing drugs from hydrogel vehicles placed either via intratympanic injection or during 
tympanostomy surgery [65–67]. While sustained release and efficacy in clearing infection and 
inflammation were observed from 2 weeks to 3 months, these systems require invasive procedures. 
Further, the gel cannot be retrieved from the middle ear if there are complications and long-term 
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toxicity effects due to degradation byproducts have not been investigated. Topical sustained 
release systems have also been investigated to improve AOM treatment in cases with intact TMs, 
including ciprofloxacin-loaded hydrogels augmented by combinations of chemical permeation 
enhancers (CPEs), which resulted in increased transtympanic permeation [57,68,69]. However, 
CPEs carry a risk of toxic side effects [70] and have been shown to be cytotoxic during the 
preclinical validation of this system, with only 20% keratinocyte viability after 3 days [68]. 
Further, recent studies suggest that outcomes may be improved when antibiotic treatment lasts 10 
or more days [71], currently unachievable by these hydrogel-only systems. Achieving this duration 
of drug release typically requires a secondary controlled release vehicle such as hydrolytically 
degradable polymer microspheres [29]. Degradable microspheres offer the ability to sustain 
delivery of drug for an extended period of time from a single, localized dose, tunability for various 
drugs and dosing ranges, and consistent daily release of therapeutic concentrations [57]. 
1.3 Chronic Tympanic Membrane Perforation 
1.3.1 Incidence and Severity of Tympanic Membrane Perforations 
Perforation of the tympanic membrane (TM) is common due to infection or trauma, and 
particularly large or chronic perforations can be non-healing [72]. Approximately 6-46% of such 
injuries are non-healing, with the remainder requiring up to 8 weeks for complete closure [73,74]. 
Even complete healing of the TM can take weeks or months, during which time patients are more 
susceptible to infection and can experience tinnitus, vertigo, or loss of hearing during the healing 
phase. The estimated prevalence of chronic TM perforation is 5 out of every 1000 patients [75]. 
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Developing nations and active military zones have been associated with even higher rates of 
traumatic TM injury, particularly due to pressure-induced rupture [76,77].  
1.3.2 Current Clinical Standards and Associated Shortcomings 
Clinical work to this point has been limited to smaller perforations, many of which heal 
spontaneously [78]. Non-healing TM perforation or rupture is thought to be due to decreased 
regenerative activity at the margin of the perforation [79]. Despite some discussion surrounding 
the correct treatment of curled or abnormal TM edges [80,81], the current standard is generally 
myringoplasty or tympanoplasty. These surgical techniques seek to close the compromised TM 
using a graft or synthetic material, which dramatically decreases the risk of infection. However, 
these interventions carry risk of temporary or permanent nerve damage, hearing loss, tinnitus, or 
dizziness, and outcomes tend to be more severe for larger perforations [82]. In the previously cited 
prevalence study, over 88% of subjects with chronic perforations were opposed to the idea of 
surgical grafting [75]. These data suggest a need for alternative treatment methods that can induce 
or accelerate healing in the context of a minimally or noninvasive, conservative treatment 
approach. 
1.3.3 Grafting, Growth Factor, and Stem Cell Treatment 
Accordingly, recent research has focused on expanding and improving treatment options 
to address the aforementioned shortcomings using standard tissue engineering strategies [23,83] . 
Naturally derived or synthetic alternatives to autologous grafts have been investigated, including 
paper patch [84,85], 3D printed polymer scaffolds [86], gel foam [80], collagen [87–89], silk [88–
 12 
91], atelocollagen [79], alloderm [92], and other natural material-derived patches [93–97]. In large 
perforations, patch administration does in fact shorten the healing time and reduce the need to 
repeat procedures but may cause increased otorrhea [80,84,85]. 
The administration of soluble factors, either alone or embedded in an appropriate scaffold 
material, has shown promise, particularly in small perforations. This includes ofloxacin [98,99], 
epidermal growth factor (EGF) [97,100,101], human umbilical cord serum [102], and fibroblast 
growth factor 2 (FGF-2) [79,103–105]. The use of FGF-2 in particular has been reported to 
modulate the rate of healing for small perforations (≤25% of total TM area) in clinical studies 
[106,107]. Some forms of FGF has also been approved by the FDA for applications such as side 
effects of bone marrow transplants [108]. 
One recent study demonstrated regeneration of a large perforation (60% of TM area) in 
Sprague Dawley rat model [109] after four weeks of non-healing. A hybrid 
polycaprolactone/collagen/alginate scaffold impregnated with mesenchymal stem cells (MSCs) 
was affixed to the remaining TM tissue using fibrin glue. MSCs are multipotent stem cells that can 
be isolated from adipose, bone marrow, or other tissues and are involved in most phases of wound 
healing [110]. All perforations treated with MSCs healed, compared to only 72% of controls. 
Similar results have been shown for embryonic stem cells [106,111] and with MSCs in separate 
mouse models [112–114]. These results tend to suggest a high regenerative capacity of MSCs, 
potentially greater than that of single growth factor (GF) administration. This may be due to a lack 
of biologically-relevant circumstances in simple soluble GF administration. For example, it has 
been shown that extracellular vesicles (EVs) serve as a significant reservoir for FGF-2 and that 
stimulatory effects on cell growth and proliferation are diminished in vesicle free media [115]. The 
binding of endogenous FGF-2 to cell-surface/extracellular proteoglycans (some of which are 
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membrane-bound on EVs) has also shown increased activity during angiogenesis [116]. This 
binding and secretion behavior is not captured in single GF administration, nor is the traditional 
gradient-like pattern of vesicle shedding characteristic of many wound healing applications [117]. 
These concerns can be addressed with controlled delivery of growth factors for tissue engineering 
applications [7]. 
 
1.4 Specific Aims and Hypotheses 
1.4.1 Specific Aim 1: Development and Testing of a Topical Controlled Release System to 
Release Clinically Relevant Therapeutic Levels. 
Sub-Aim 1a: Development and testing of a topical controlled release system to release clinically 
relevant antibiotic levels. 
Hypothesis 1a: This aim tested the hypothesis that a thermoresponsive gel/microsphere system 
will encapsulate and release therapeutically relevant levels of antibiotics for treatment of acute 
otitis media, with in vitro safety and efficacy demonstrated by lack of cytotoxicity and ability to 
kill bacterial culture. 
 
The objectives of this sub-aim were to: 
• Optimize encapsulation and release of antibiotics, specifically ciprofloxacin and 
ceftriaxone, from MS in a linear manner over 14 days. 
• Characterize morphology and material properties of microspheres and gel. 
• Test preliminary safety and efficacy of microsphere formulations using in vitro cytotoxicity 
and bacteria killing assays. 
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Sub-Aim 1b: Development and testing of a topical controlled release system to encapsulate and 
release stem cell secretome. 
Hypothesis 1b: This aim tested the hypothesis that a thermoresponsive gel/microsphere system 
will encapsulate and release free and extracellular vesicle-bound pro-regenerative factors from 
mesenchymal stem cell conditioned media, with in vitro safety and efficacy demonstrated by 
scratch wound healing and lack of cytotoxicity. 
 
The objectives of this sub-aim were to: 
• Optimize encapsulation and release of mesenchymal stem cell conditioned media for 
release of extracellular vesicles and soluble growth factors relevant to tympanic membrane 
regeneration over 21 days. 
• Characterize morphology and material properties of microspheres. 
• Test preliminary safety and efficacy of microsphere formulations using in vitro cytotoxicity 
and scratch wound proliferation assays. 
1.4.2 Specific Aim 2: Assessment of Transtympanic Permeability, Safety, and Efficacy 
Using Ex Vivo and In Vivo Acute Otitis Media Models. 
Hypothesis: This aim tested the hypotheses that sufficient levels of released drug can diffuse 
across the tympanic membrane in an ex vivo model of transtympanic permeability and that the new 
drug release system can be safe and effective in vivo, as demonstrated by testing for clearance of 
infection and lack of irritation due to drop placement. Results of the ex vivo studies helped guide 
development in Specific Aim 1a and serve as justification to proceed to in vivo studies. 
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The objectives of this aim were to: 
• Quantify ciprofloxacin penetration through tympanic membranes in an ex vivo setup. 
• Determine preliminary in vivo efficacy of ciprofloxacin and ceftriaxone-loaded 
microsphere/gel drop in chinchilla acute otitis media disease model. 
• Determined preliminary safety profile of blank, ciprofloxacin, and ceftriaxone-loaded 
microsphere/gel drop in chinchilla acute otitis media disease model. 
1.4.3 Specific Aim 3: Demonstration of Tympanic Membrane Healing In Vivo. 
Hypothesis: This aim tested the hypothesis that mesenchymal stem cell conditioned media and 
conditioned media-loaded polymer microspheres/gel drop can increase wound healing of in vivo 
tympanic membrane perforation with a lack of irritation due to placement of materials. These 
studies help further inform development of the delivery system in Specific Aim 1b. 
 
The objectives of this aim were to: 
• Determine preliminary efficacy of MSC CM and CM-loaded microspheres in a guinea pig 
non-healing TM perforation model. 
• Determine preliminary safety profile of MSC CM and CM-loaded microspheres in a guinea 
pig non-healing TM perforation model. 
1.4.4 Impact of Dissertation and Specific Aims 
There is a clear need for safe, simple, and effective drug delivery to the ear. The goal of 
the studies described herein was to develop and test an innovative method of sustained presentation 
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of antibiotics and stem cell secretome to and across the TM. Previous work by this group has 
shown that ocular permeability barriers can be overcome using a validated drug delivery system 
including a topical, thermoresponsive gel depot containing drug-loaded PLGA microspheres 
[118,119]. Although there are similarities in these topical routes of administration which indicate 
the potential for the system to be effective as an otic topical drug delivery system, the drug 
presentation to the ear anatomy is quite different from ocular presentation and lends to novelty of 
the system. Therefore, the sustained presentation afforded by the stable gel depot is proposed to 
allow a therapeutically relevant amount of drug to penetrate the TM without harmful additives. 
We hypothesized that development and optimization of a novel drug delivery system can 
noninvasively sustain localized release of antibiotics and stem cell secretome to the TM and middle 
ear, as demonstrated by in vitro, ex vivo, and in vivo testing. 
Development of materials in Specific Aim 1 can establish a drug delivery platform for 
topical treatment of the TM and middle ear, specifically with optimization of MS for release of 
antibiotics, ciprofloxacin and ceftriaxone, as well as mesenchymal stem cell conditioned media. 
This also allowed for development of methods for tailoring of this drug delivery platform for 
different release profiles and durations for various treatment needs and expanding the platform for 
encapsulation of other therapeutics for delivery both to the ear and other applications. In vitro 
material safety and efficacy testing in Specific Aim 1 also served as indication of preclinical 
potential and justification to proceed with in vivo testing upon optimization of the materials. 
In addition to in vitro efficacy testing in Specific Aim 1a, Specific Aim 2 investigated ex 
vivo permeability of antibiotic released from hydrolysable MS retained in gel carrier compared to 
permeability due to topical administration of standard antibiotic drops used clinically. As the goal 
of this dissertation work was to avoid chemical permeation enhancers for use with intact TMs, 
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these ex vivo permeability studies served as indication that sufficient antibiotic levels can permeate 
into the middle ear compared to the standard topical drops and based on antibiotics’ minimum 
inhibitory concentration for clearance of the most prevalent bacteria present in OM. In conjunction 
with in vitro efficacy data, these studies served as justification to proceed to testing in an animal 
model of OM, which provided insight into in vivo safety and efficacy, as well as future directions 
for further optimization of materials for improved efficacy. 
Specific Aim 3 expanded upon in vitro efficacy results in Specific Aim 1b to determine 
effects on wound healing and development of a preliminary safety profile due to administration of 
CM-loaded MS/gel treatment compared to treatment with topical CM drops. This will build upon 
and add to prior studies indicating positive effects on wound healing due to growth factor and/or 
stem cell therapy, allowing for further development of stem cell secretome-based therapies. This 
study also allowed for development and future directions for optimization of a guinea pig model 
of chronic TM perforation, as well as providing insight on best practices for administration and 
removal of the drug delivery system to improve upon potential for eventual clinical translation. 
The drug delivery platform is unique in that it would require only a single drop for the 
duration of treatment and will provide clinically relevant levels of therapeutic to the target area in 
a controlled and safe manner. Gel-based drug delivery to the middle and inner ear has previously 
been shown to be possible with intratympanic injection or facilitated by chemical permeation 
enhancers [57,65,67,120]. Intratympanic injections involves an invasive procedure and CPEs 
come with risk of side effects due to the harsh nature of the chemical additives [70]. In contrast, a 
topical controlled release system that works via continuous drug presentation at the TM may offer 
an alternative treatment option. Furthermore, the isolation and therapeutic use of MSC secretome 
is an emerging field that therefore endows all new methods and discoveries with a level of 
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innovation. The application of such secreted material in the ear, particularly for TM regeneration, 
is (to our knowledge) unexplored, given that it is such a specialized field. However, the ear offers 
easy access and has shown potential compatibility with MSC-based regenerative strategies [109], 
making it an ideal system for advancing the knowledge and translational potential of secretome-
based therapeutics. This proposed system may be the first fully acellular yet cell-mimetic tissue 
engineering approach to treatment of TM perforation. 
Patient compliance may be dramatically improved, as only a single, clinician-administered 
drop will be needed for treatment. Side effects may be mitigated due to localization to the middle 
ear and minimization of applied drug. Removal of the non-degradable gel upon completion of 
treatment duration may further reduce long-term adverse side effects due to lingering material or 
degradation products, though specific removal techniques must further be investigated. 
Furthermore, our system uses well-characterized biodegradable polymer matrices, proven 
safe and capable of higher initial loading, endowing our system with sustained drug release in a 
longer and more consistent manner than current investigational methods [121]. The proposed 
treatment modality has shown success in topical ocular delivery [118,119,122], and thus, delivery 
to the ear is a natural and important extension of this unique technology. Further optimization of 
the CM-loaded MS formulation would allow for development of a precise regenerative material 
that may be more suitable to the distinctive environment surrounding the TM than cell therapy, 
particularly the potential for increased FGF activity through inclusion of EVs in the encapsulated 
secretome. Finally, our methods result in biomaterials that behave more like stem cells than 
artificial vesicles or single growth factors with capability of releasing regenerative factors and EVs 
in a gradient-like pattern. Therefore, we have developed a drug delivery platform for otic drug 
delivery that can be adapted for a variety of therapeutics, treatment durations, and conditions. 
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2.0 Development and Testing of a Topical Controlled Release System to Release Clinically 
Relevant Antibiotic Levels 
2.1 Introduction 
2.1.1 Ciprofloxacin Use for Otitis Media Treatment 
Ciprofloxacin is an ideal candidate for encapsulation and has been extensively utilized in 
the aforementioned gel-based studies due to local toxicity effects of other standard topical 
antibiotics including tobramycin, neomycin, and gentamycin [53,123], effects which have not been 
observed due to ciprofloxacin treatment [124]. It is current standard prescribed oral and topical 
antibiotic due to a long track record of safety and efficacy as well as FDA approval. Further, 
ciprofloxacin is a fluoroquinolone that affects most of the microorganisms responsible for OM, 
and although it is a rarely occurring pathogen in AOM, ciprofloxacin is in fact the only antibiotic 
that treats Pseudomonas-based OM [53,124]. Minimum inhibitory concentrations (MIC) to clear 
50-90% of Haemophilus influenzae and Streptococcus pneumonaie isolates are, respectively, 0.03 
and 0.5-2µg/mL [59,60]. Because of these factors, several previous studies of sustained or 




2.1.2 Ceftriaxone Use for Otitis Media Treatment 
Several of the bacterial strains most common in OM, including H. influenzae and S. 
pneumoniae readily form biofilms, which may inhibit the effectiveness of antibiotic therapy 
[10,54]. Although less commonly used than other treatments, the current treatment when there is 
suspicion of resistance or low patient compliance is a three-day course of intramuscular ceftriaxone 
treatment, which has shown to be as effective as a two-week treatment course of amoxicillin and 
has proven effective in treatment of penicillin-resistant infections and persistent Streptococcus-
based infections [125–129]. Ceftriaxone is administered via intramuscular injection rather than 
orally due to poor permeability and instability in the gastrointestinal environment. To address this 
issue, one recent study investigated oral delivery of ceftriaxone via a nanoemulsion-based drug 
delivery system in conjunction with permeation enhancers [130]. Ceftriaxone is an effective 
treatment for clearance of both gram-positive and gram-negative bacteria, with MIC required to 
clear 90% (MIC90) of various bacteria ranging 0.03-2µg/mL, specifically MIC90 of 0.03µg/mL for 
H. influenzae and MIC50 and MIC90 of 0.06µg/mL and 2µg/mL for S. pneumonaie [59,60,131]. 
Therefore, to maximize efficacy of treatment, ciprofloxacin and ceftriaxone were chosen 
for encapsulation in the drug delivery system described herein. Further, to our knowledge, 




2.2 Materials and Methods 
All materials were obtained from Sigma-Aldrich (St Louis, MO) unless otherwise noted. 
2.2.1 Ciprofloxacin-loaded Microsphere Formulation 
Ciprofloxacin-loaded microspheres (MS) were prepared using a water-in-oil-in-water 
(W/O/W) double emulsion procedure adapted from previous work [38,121,132]. To prepare the 
MS, 200mg poly(lactic-co-glycolic) acid (PLGA) (MW 24-38 kDa; viscosity 0.32-0.44dL/g) were 
dissolved in 4mL dichloromethane to which 250µL of 100mg/mL ciprofloxacin in 1M acetic acid 
was added. The dissolved drug and polymer mixture were then sonicated for 10 seconds at 30% 
amplitude (EpiShear Probe Sonicator, Active Motif, Carlsbad, CA) followed by homogenization 
in 60mL of 2% poly(vinyl alcohol) (PVA) (Polysciences, Warrington, PA) for 1 minute at 
7000rpm (Silverson L5M-A, East Longmeadow, MA). The resulting liquid-phase emulsion was 
added to 80mL of 1% PVA and stirred at 600rpm for 3 hours, resulting in precipitation of solid 
MS. Drug-loaded and blank MS, fabricated by substituting deionized (DI) water for aqueous drug, 
were then washed 4 times by centrifugation, resuspended in DI water, flash frozen in liquid 
nitrogen, and lyophilized for 48-72 hours (Benchtop Pro, SP Scientific, Warminster, PA). 
2.2.2 Ceftriaxone-loaded Microsphere Formulation 
Ceftriaxone-loaded MS were prepared using similar steps as above via an oil-in-water 
(O/W) single emulsion procedure in which 200µL of a 30mg/mL solution of ceftriaxone in 
dimethyl sulfoxide (DMSO) was added to dissolved polymer and followed by homogenization and 
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subsequent precipitation, lyophilization, and washing steps as described above, with an appropriate 
amount of NaCl added to PVA to balance the osmolality of the ceftriaxone solution. Blank MS 
were fabricated using the same methods, with DMSO alone substituted for ceftriaxone dissolved 
in DMSO. 
2.2.3 Antibiotic-loaded Microsphere Morphology Characterizations 
Size, shape, porosity, and drug loading and release were characterized for each set of MS 
prepared. Scanning electron microscopy (SEM) was used to examine shape and morphology of all 
MS formulations (JEOL JSM 6335F, Peabody, MA). MS diameter was quantified by volume 
impedance measurements with mean and standard deviation determined for n=15,000 MS per 
sample (Multisizer, Beckman Coulter, Brea, CA). Density of MS was determined via a 
measurement device custom-made using a 1mL syringe (Figure 3). A known mass, approximately 
15-30mg, of MS was added and MS packed by pushing down on the plunger, allowing for volume 




Figure 3: Custom syringe mechanism to measure density of microsphere formulations. 
Microspheres 
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2.2.4 In Vitro Drug Release from Antibiotic-loaded MS 
In vitro drug release kinetics were determined using 10mg of MS suspended in 500mL 
phosphate buffered saline (PBS) and continuously rotated at 37ºC. The supernatant was removed 
via centrifugation every 24 hours and replaced with fresh PBS. For each formulation, total drug 
loading was taken to be cumulative drug release when all MS were fully degraded, and therefore 
drug release was exhausted, after 14 days. 
Ciprofloxacin concentration in the supernatant was quantified via UV/Vis absorbance 
measures taken at 246nm (SoftMax Pro 5, Molecular Devices, Sunnyvale, CA), with background 
signal from blank MS subtracted from each measurement and regressed against the standard curve, 
validated for 1-10µg/ml. High performance liquid chromatography (HPLC; 1220 Infinity LC, 
Agilent Technologies, Santa Clara, CA) using the following settings was used to confirm: 
Kromasil C18 column (4.6mm x 150mm, 3.5µm particles), 10µL injection volume, 80:20 
acetonitrile:0.1% trifluoracetic acid mobile phase, 1mL/min flow rate, detection at 275nm. This 
method has been reported previously [57] and validated for the range 100ng/mL-10mg/mL.  
Ceftriaxone concentrations were quantified using the following settings adapted from 
previously reported studies [133]: reverse phase Zorbax Eclipse Plus C18 Column (4.6mm × 150 
mm, 5μm particles), 20µL injection volume, 70:5:25 HPLC water:acetic acid:acetonitrile mobile 
phase, flow rate 1mL/min, detection at 254nm.  
2.2.5 Cytotoxicity Assays 
Cytotoxicity of the MS was analyzed by both Vybrant MTT (3-(4,5-dimethylthiazol-2yl)-
2,5-diphenyltetrazolium bromide) Cell Proliferation Assay Kit and LIVE/DEAD 
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Viability/Cytotoxicity Kit (Thermo Fisher Scientific, Waltham, MA). Studies were carried out 
using human primary epidermal keratinocytes (ATCC, Manassas, VA), the primary cell type found 
in TM tissue [125]. To perform the assay, ~3,000 cells/well were plated in 96 well plates and 
incubated in 200µL Dermal Cell Basal Medium with Keratinocyte Growth Kit (ATCC) for 24h at 
37°C with 5% CO2 to achieve a monolayer. Cells with medium only were used as the positive 
control for viability in both assays and cells incubated with 70% methanol for 5-10mins prior to 
each assay were used as a negative control, per kit instructions. All test groups included 100µL 
medium and 100µL test material: PBS, 1µg/mL ciprofloxacin (CIP), 5µg/mL ceftriaxone (CFX), 
1mg blank MS, 1mg CIP MS, 1mg CFX MS, blank MS releasate, CIP MS releasate, CFX MS 
releasate. Releasates were collected via the same methods as described above, with only 24h 
releasates used for this study as highest release for both antibiotics are seen after 24h: 0.79 ± 
0.13µg ciprofloxacin and 1.58 ± 0.04µg ceftriaxone. Once a monolayer of cells was achieved, 
treatment groups were applied and incubated for an additional 24h. Microspheres were also applied 
(1mg MS in 200µL basal medium) to wells with no cells to account for any background signal.  
MTT assay was performed by additional incubation for 4h with 10µL MTT stock solution, 
followed by incubation for 10mins with 50µL DMSO. Absorbance in each well was then 
determined via spectrophotometer at 540nm. Percent viability was determined by normalizing to 
100% viability in the positive control group. 
For the LIVE/DEAD assay, the same test groups were used as above. The assay was 
performed via addition of 100µL LIVE/DEAD working solution (2µm calcein AM/4µm ethidium 
homodimer-1) to each well and incubating for 45 minutes at 25°C prior to measuring absorbance 
at 530nm and 645nm to detect live and dead cells, respectively. Percent viability was determined 
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by normalizing to 100% viability in the positive control group. The mean and standard deviation 
absorbance values for both assays were determined for n=3 samples in each test group. 
Gel cytotoxicity has been previously investigated and reported by Fedorchak et al [38].  
2.2.6 In Vitro Bacteria Killing 
Non-typeable Haemophilus influenzae (strain 86-028NP) bacteria were cultured at a 
concentration of approximately 106 CFU/mL. To these bacterial cultures, treatment groups of 
blank MS, ciprofloxacin-loaded MS, ceftriaxone-loaded MS, 1µg/mL ciprofloxacin, 5µg/mL 
ceftriaxone, or no treatment were applied. All MS groups were added in a concentration of 10mg 
MS/mL bacterial culture medium to approximate intended treatment dose of 10mg MS, containing 
2.56 ± 0.14µg ciprofloxacin or 2.71 ± 0.03µg ceftriaxone. Concentrations of free antibiotic for 
positive controls were chosen based on literature values for minimum inhibitory concentrations of 
ciprofloxacin and ceftriaxone to H. influenzae and other relevant bacteria [59,60] and were 
confirmed by this group. After incubation for 24-48 hours at 37°C, viable bacteria were counted 
by serially diluting the cultures followed by plating on agar plates and incubating at 37°C for 24-
48 hours.  
2.2.7 Thermoresponsive Gel Formulation and Scale Up 
The gel was prepared via free radical polymerization of 500mg N-isopropylacrylamide 
(NIPAAm) (Fisher Scientific, Waltham, MA) and 500µL poly(ethylene glycol) (PEG; MW 
~200kDa), in the presence of 9.44mL DI water, 50µL of 100mg/mL ammonium persulfate (APS), 
and 20 µL tetramethylethylenediamine (TEMED). The gel precursor was refrigerated for 24h and 
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then washed in DI water at ~40ºC. This formulation is a 10x scale up of a previously reported gel 
fabrication method [37,38,135].  
2.2.8 Thermoresponsive Gel Characterization 
The gel formulation underwent testing for degradation rate, swelling ratio, and lower 
critical solution temperature (LCST) as previously reported [38,135].  LCST was determined via 
UV/Vis absorbance measurements at 415nm over a temperature range of 25-40°C, increased by 
1°C increments and allowing 15 minutes between readings for temperature equilibration.  
Degradation rate was determined by comparing solid fraction of liquid gel at baseline and 
every 7 days for 28 days in the gel phase, with the gel stored in PBS at 37°C. Solid fraction was 
quantified by the following formula, where 𝑊𝑖 refers to mass of gel on day 𝑖 = 7, 14, 21, 28: 
 
 𝑆𝑜𝑙𝑖𝑑 𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛 =  
𝑊𝑖 −ave(𝑊𝑑)
𝑊𝑖
  Equation 2-1 
 
Swelling ratio was determined by placing 100µL of gel in 37°C for 72h or until the liquid 
was fully evaporated. Dry mass was compared to swollen mass prior to evaporation for n=3 
samples. Swelling ratio (SR) was determined by the following formula, where Ws refers to mass 
of swollen gel in water and Wd refers to dry gel: 
 
 







To qualitatively analyze retention of gel in the ear canal, a transparent plastic human ear 
model was used. A 300µg/mL solution of fluorescein isothiocyanate (FITC) in DI water was 
prepared and 50µL of the solution was added and mixed with 200µL of gel. Using a 1mL syringe 
with capillary tubing attached to the tip, 100µL of fluorescently dyed gel was applied to the ear 
canal on the tympanic membrane. The model was placed in a 100mL beaker with the ear canal 
facing up and left in a 37°C incubator for 30 minutes for the gel to solidify. After 30 minutes, the 
ear model was removed from the beaker and placed in the incubator with the ear canal 
perpendicular to the bottom of the incubator. The ear model was evaluated by visual inspection 
and photography after 2, 3, and 24 hours. 
2.2.9 Auditory Brainstem Responses 
Animal studies conformed to the NIH Guide for Care and Use of Laboratory Animals and 
all procedures were approved by the University of Pittsburgh IACUC. Two groups of n=3 guinea 
pigs were used to test the effect of the administration of the gel system on conductive hearing 
sensitivity using the auditory brainstem response (ABR) with free-field sound presentation. Each 
animal underwent ABR testing under the following conditions: both ears unplugged, left ear 
plugged with foam and dental silicone, left ear plugged and gel applied to the right ear, gel in right 
ear after removing plug from left ear, both ears unplugged after removal of gel. To plug the left 
ear, a piece of foam was inserted into the ear canal, covered with vinyl polysiloxane impression 
material (Examix NDS, GC America, Alsip, IL), and allowed to set for 5 mins. Gel was instilled 
in volumes of 25 or 100 µL to the right ear using a 200µL pipette and allowed to set for 5 mins. 
Gelation and presence of gel in the ear canal were confirmed via visual inspection. 
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ABR experiments were performed under 1-2% isoflurane anesthesia, with ABR acquired 
via three subcutaneous electrodes (27-gauge needle electrodes, Rochester Electro-medical) placed 
at standard locations (signal – vertex of skull, reference – below pinna overlying mastoid, ground 
– below the other pinna). Click stimuli (100µs long) with alternating polarity repeating every 
100ms (10 per second) were presented ~1000 times each at 14 sound levels (5dB-75dB in 5dB 
steps), with the loudest sound level presented first (total duration ~27min). ABR signals were 
collected at 30kHz sampling rate and bandpass filtered (200-2000Hz). A rejection criterion of 
peak-to-peak response greater than 50µV was used to discard trials that included potential artifacts. 
The distributions of baseline fluctuations at each sound level was obtained from a 2.5-ms segment 
of the ABR recording just prior to the onset of each click. Wave 1 of the ABR at the loudest 
stimulus level was defined as the first positive peak after stimulus onset. At the other sound levels, 
wave 1 was defined as the first positive peak occurring at a time equal to or later than wave 1 at 
the loudest level. The peak-to-peak amplitude (wave 1 trough to wave 2 peak) was taken as the 
ABR amplitude on each trial. The hearing threshold of the tested ear was taken to be the lowest 
sound level at which the mean ABR amplitude exceeded 4 standard deviations of the distribution 
of baseline fluctuations. 
2.2.10 Statistical Analysis 
Data for in vitro release assays, MS density, gel degradation, and cytotoxicity testing are 
represented as average ± standard deviation for at least n=3 samples. Volume impedance 
measurements of MS diameter are represented as average ± standard deviation for n=15,000 
particles per sample. Gel degradation data were compared using Student’s t-test at each time point. 
Auditory brainstem response threshold shifts from baseline were analyzed using Kruskal-Wallis 
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test with Dunn’s post-hoc testing within each group and Mann Whitney U test for comparison 
between applied gel volumes. All statistical analyses were performed using GraphPad Prism 
software (San Diego, CA).  
2.3 Results 
2.3.1 Ciprofloxacin-loaded MS Release Profile 
Ciprofloxacin release was quantified via HPLC using the standard curve shown in Figure 
4. Release can also be quantified via spectrophotometry using the standard curve shown in Figure 
5. Release of ciprofloxacin follows an approximately linear pattern over 14 days, resulting in 




Figure 4: Ciprofloxacin standard curve determined using high performance liquid chromatography. 
 



























Figure 6: In vitro antibiotic release from 10mg ciprofloxacin-loaded microspheres over 14 days. Error bars 
represent the mean ± standard deviation for n=3 samples. 
 


























































2.3.2 Ceftriaxone-loaded MS Release Profile 
Release was quantified via HPLC using the standard curve shown in Figure 7. Ceftriaxone-
loaded MS demonstrate 58% burst release on Day 1 followed by linear release over 14 days, 




Figure 7: Ceftriaxone standard curve determined using high performance liquid chromatography. 
 























Figure 8: In vitro antibiotic release from 10mg ceftriaxone-loaded microspheres over 14 days. Error bars 
represent the mean ± standard deviation for n=3 samples. 
 
2.3.3 Antibiotic-loaded MS Morphology 
Scanning electron microscopy images (Figure 9) confirm spherical morphology of MS. 
Volume impedance measurements of microsphere diameter (Table 1) confirm visual analysis of 
microsphere size with SEM  and are consistent with previously observed diameter ranges for 
similar microsphere formulations developed by this group [114,115]. Ceftriaxone MS diameter 
was adjusted to larger diameter by decreasing homogenization speed during fabrication to reduce 


































Figure 9: Scanning electron microscopy images of A) blank, B) ciprofloxacin-loaded, and C) ceftriaxone-
loaded microspheres. Scale bar = 10µm. 
 
Table 1: Average diameters and densities of blank, ciprofloxacin, and ceftriaxone microsphere formulations. 
 
Microsphere type Diameter (µm) Density (mg/mL) 
Blank 7.85 ± 5.37 776.9 ± 21.6 
Ciprofloxacin 6.88 ± 3.36 752.5 ± 22.6 
Ceftriaxone 16.69 ± 5.65 650.7 ± 25.1 
 
2.3.4 Cytotoxicity Due to Antibiotic-loaded MS and Releasates 
Both MTT and LIVE/DEAD viability assays suggest acceptable levels of cytotoxicity 
[136–138] following 24h of treatment with aqueous drug, blank and drug-loaded microspheres, 
and microsphere releasates (Figure 10). Aqueous ciprofloxacin and ceftriaxone resulted in, 
respectively, 90.4 ± 5.9% and 128.1 ± 8.0% cell viability in the MTT assay and 101.3 ± 0.1% and 
94.2 ± 0.2% viability in the LIVE/DEAD assay. Blank, ciprofloxacin-loaded, and ceftriaxone-
A B C 
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loaded MS resulted in, respectively, 66 ± 10.7%, 67.4 ± 7.1%, and 90. 9± 6.0% viability in the 
MTT assay and 103.6 ± 2.2%, 90.3 ± 4.8%, and 99.3 ± 3.1% viability in the LIVE/DEAD assay. 
Releasates from blank, ciprofloxacin-loaded, and ceftriaxone-loaded MS resulted in, respectively, 
68.8 ± 10.2, 121.8 ± 4.0%, and 86.8 ± 3.8% viability in MTT assay and 97.1 ± 0.8%, 96.5 ± 0.2%, 
and 57.6 ± 0.4% viability in the LIVE/DEAD assay. Positive controls of medium and PBS resulted 
in 100 ± 8.2% and 112.8 ± 4.5% viability in the MTT assay and 100 ± 1.2% and 98.8 ± 0.5% 
viability in the LIVE/DEAD assay. Negative control of 70% methanol resulted in 6.2 ± 0.2% and 
7.7 ± 0.01% viability in the MTT and LIVE/DEAD assays, respectively. 
The MTT assay is a commonly used method to test medical device-related cytotoxicity; 
discrepancies between cell viability percentages due to use of different cytotoxicity assays have 
previously been noted, with the MTT assay more sensitive to detection of cytotoxicity [139,140]. 
These results support this observation and suggest the microspheres and releasates will be 
biocompatible in vivo. Lack of cytotoxic response due to application of gel has been previously 





Figure 10: Cytotoxicity due to antibiotics, microspheres, and releasates. Cell viability assays show acceptable 
levels of cytotoxicity due to application of blank and drug-loaded microspheres and microsphere releasates to human 
dermal keratinocytes for 24h. Error bars represent mean ± standard deviation for n=3 samples except Medium, PBS, 
Blank MS, and Blank releasate groups which have n=6 samples. Red dashed line indicates 70% viability, the 
minimum recommended for medical devices. 
 
2.3.5 In Vitro Bacteria Killing 
All H. influenzae bacteria were cleared after treatment for 24h and 48h with ciprofloxacin-
loaded MS, ceftriaxone-loaded MS, free ciprofloxacin, and free ceftriaxone, with significantly 
reduced bacterial count compared to treatment with blank (no drug loaded) MS and no treatment 
control (Figure 11). No significant difference between MS groups and releasate groups indicates 






















Figure 11: In vitro clearance of bacteria treated with antibiotics and microspheres (MS). Clearance of H. 
influenzae after 24-48h due to treatment with ciprofloxacin (CIP) MS, ceftriaxone (CFX) MS, blank MS, 1µg/mL 
CIP, 5µg/mL CFX, or no treatment control (CTL). MS were applied in concentration of 10mg/mL bacterial culture. 
Errors bars represent the mean ± standard deviation for n=8 samples for CIP MS and CFX MS groups and n=4 
samples for all other groups. Red dotted line indicates complete bacterial clearance. 
 
2.3.6 Thermoresponsive Gel Characteristics 
Swelling ratio, which indicates increase in gel weight due to water absorption, was 
calculated to be 5.13 ± 0.52 for n=5 gel samples and is comparable to previous smaller batch results 
[38,135] and other groups investigating pNIPAAm based gels [34]. LCST (Figure 12) was 
determined via spectrophotometric absorbance measurements as ~35.5°C, which is also 
comparable to previous results and indicates gel can shed its excess water content and transition 
to solid form at physiological temperatures [38]. No significant change in solid fraction over 28 

























Figure 12: Lower critical solution temperature (LCST) of thermoresponsive pNIPAAm gel. LCST was 






Figure 13: Degradation testing of pNIPAAm gel over 28 days. Lack of degradation was determined by observing 
no change in solid fraction at 37°C over 28 days. Error bars represent the mean ± standard deviation for n=3 













































Thermoresponsive gel was easily applied to the TM of an adult human ear model and 
retention was confirmed after 3 hours inversion at 37°C (Figure 14). The gel was left in the ear 
model for up to 24h, however the gel dried due to low-moisture conditions in the incubator, which 
should not occur in vivo due to humidity in the external auditory canal [141]. These results suggest 




Figure 14: Model of drug delivery system retention. Administration of 100µL gel/MS suspension (gel stained 
with fluorescein for visualization) to TM in synthetic human ear model (A) using a modified syringe applicator (B). 
Retention was confirmed after 3 hours inversion (C,D). 
 
2.3.7 Auditory Brainstem Responses 
Auditory brainstem responses (Figure 15) in two groups of guinea pigs indicate application 
of gel to the ear canal results in a similar threshold shift as application of an earplug. All parameters 
were the same for both groups except volume of gel applied. The testing scenario of 100µL 
contained n=2 animals, compared to n=3 animals in all other testing scenarios, due to difficulty of 
A 
B C D 
90° 
t = 0h t = 3h 
Fluorescein-stained gel 
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vinyl polysiloxane earplug removal causing perforation of the tympanic membrane in the left ear, 
confounding the gel-only ABR results for that animal. Subsequent groups consisted of a piece of 
foam applied to the ear prior to vinyl polysiloxane to prevent TM perforation upon removal. In 
both groups, there was no significant difference in threshold shift between one ear plugged with 
ear plug and one ear with 25µL or 100µL gel instilled. In both of these testing scenarios, the other 
ear was left unplugged. There was no significant difference in hearing threshold shift due to 
different gel volumes applied. Threshold shift of sound pressure level due to one ear containing 








Figure 15: Threshold shifts recorded via auditory brainstem response (ABR) in guinea pigs. Each group was 
tested with both ears unplugged as baseline, left ear plugged with earplug, and right ear with gel applied. Group 1 
received a 25µL gel drop and Group 2 received a 100µL drop. Representative ABR traces (A) and peak to peak 
signal to noise ratio (SNR) (B) are shown along with threhold shift relative to baseline for each group (C). Threshold 
shift in sound pressure level (SPL) are indicated with a box (A). Threshold shifts are represented as mean ± standard 
deviation for n=3 animals per group (n=2 for 100µL gel drop testing scenario). Threshold shifts within each group 
were analyzed for significance (*p<0.05) with Kruskal-Wallis test and Dunn’s post-hoc testing. Significant 
differences were observed due to application of earplug and gel compared to baseline but no significance was 
observed between earplug and gel application. Significant differences in threshold shift due to applied gel volume 







As the leading indication for antibiotics prescribed to pediatric patients in the United States, 
acute otitis media is responsible for over 20 million physician visits annually for the 80% of 
children who experience AOM [39–41]. In addition to the high incidence of physician visits, 
recurrent AOM can develop into chronic AOM which may require expensive and invasive surgical 
intervention and/or result in detrimental long-term effects on hearing, speech, and learning [12,45–
50]. Current standards of treatment remain oral antibiotics, which come with risk of systemic side 
effects and rise of antibiotic resistance [10,41,53,54], and topical antibiotic drops, which come 
with issues of patient noncompliance due to frequency of dosing regimen and difficulty of 
administration and risk of local and systemic side effects due to high drug concentration required 
to overcome permeability barriers in the TM [57,61–64]. For these reasons, drug delivery systems 
involving thermoresponsive hydrogels with or without degradable microspheres have been 
investigated in previous research studies [57,65,67–69,120]. The drug delivery system developed 
by our group aims to improve on these previous studies by incorporating hydrolysable antibiotic-
loaded polymeric MS to further control drug release into a thermoresponsive, nondegradable gel 
carrier that can be applied topically to the TM without need for potentially harmful chemical 
permeation enhancers. 
In vitro release data indicate MS can release sufficient drug to treat the most common 
bacterial strains present in acute otitis media. Minimum inhibitory concentration to clear 90% 
(MIC90) of H. influenzae is 0.03µg/mL and 1-2µg/mL for S. pneumonaie [59,60,131]. Bacteria 
killing studies confirmed that release from antibiotic-loaded MS can kill all H. influenzae bacteria 
in an in vitro solution over 24-48 hours. A standard dose duration for AOM antibiotic prescriptions 
is 7-14 days [58,71,128], therefore microsphere release was tailored to last the full treatment 
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duration. High initial antibiotic concentration followed by continuous presentation has been shown 
to be effective against non-responsive bacteria and biofilms, therefore this release pattern is 
desirable [125–127,129,142].  
To increase clinical translation potential, materials with a proven track record of safety 
were used in this study. Ciprofloxacin and ceftriaxone are currently frequently used clinically and 
PLGA-based materials have a strong track record of approval by the United States Food and Drug 
Administration [15,20,23]. In vitro cell viability results shown in Figure 10 confirm these findings 
with two different cytotoxicity assays [139,140], with minimum acceptable cell viability [136–
138] achieved due to treatment with antibiotics, blank and antibiotic-loaded microspheres, and 
microsphere releasates. MS were applied directly to the cells in a concentration of 1mg MS/200µL 
media, resulting in approximately 70% cell viability after 24h. This is a high concentration of MS 
applied to cells, representing a worst-case scenario for cytotoxicity; however, this concentration 
still yields an acceptable level of in vitro cell toxicity with less toxicity expected in vivo and 
clinically due to less concentrated presentation and shielding by the gel carrier.  
Cell viability due to thermoresponsive gel has been previously investigated by this group, 
with acceptable cell viability achieved after washing steps [38]. For use in this study, gel 
production was scaled up tenfold and desired characteristics were maintained, indicating potential 
for larger scale production for clinical use. The gel is used as a carrier to improve retention of 
drug-loaded MS in situ and prior ocular studies by this group indicate similar efficacy in vivo with 
and without gel, but gel allows for non-invasive, simpler administration and retention [38,121]. 
Gel is nondegradable to improve its efficiency as a carrier for retention and to reduce potential for 
toxicity due to degradation products.  
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Auditory brainstem recording studies shown in Figure 15 demonstrated no significant 
difference in hearing threshold shift due to the two different gel volumes applied (25µL and 
100µL), indicating instilled gel/MS volume can be scaled up if needed to increase drug 
concentrations presented to the TM. Threshold shift of sound pressure level relative to noise floor 
due to one ear containing either an earplug or gel was significantly different compared to both ears 
unplugged. This suggests that mass effect from gel/MS treatment would have a temporary 
conductive effect on hearing for the treatment duration. However, there is an inherent temporary 
conductive hearing loss in cases of otitis media due to bulging of the inflamed tympanic membrane 
[52,143,144], therefore minimal attenuation of hearing during treatment duration is not expected 
to greatly affect patient quality of life and treatment can help prevent permanent sensorineural 
hearing loss, a side effect of chronic otitis media [47–50]. Further studies are needed to evaluate 
long term ototoxicity of the biomaterials, with an expanded look at the topical safety of ceftriaxone 
in particular, using longitudinal ABR testing to determine effect on hearing sensitivity during 
treatment and at a time point after treatment duration has been completed [65,69,145,146]. 
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3.0 Assessment of Transtympanic Permeability, Safety, and Efficacy using Ex Vivo and In 
Vivo Acute Otitis Media Models 
3.1 Introduction 
Animal models are necessary for preclinical determination of safety profiles and treatment 
efficacy, as well as to inform further development and improvement of treatment mechanisms, 
including drug delivery systems [147–149]. For topically applied drug delivery systems, ex vivo 
permeability experiments, inform development of the system prior to proceeding to in vivo studies. 
In addition to intratympanic [145] and transtympanic [44,68] delivery systems, permeability 
experiments are standard for other topical delivery systems, including transdermal and 
transcorneal [44,68,149]. 
The tympanic membrane, primarily composed of keratinocytes [134], has similar 
permeability barriers to the skin with the hydrophobic outermost layer, the stratum corneum, acting 
as the primary barrier to permeability of topically applied treatments [44,70,148,149]. To bypass 
this barrier, topical treatments have incorporated chemical permeation enhancers (CPEs) 
[70,148,149] or employed the use of microneedle arrays (MNAs) [150], among other mechanisms. 
Molecules generally permeate the stratum corneum by following a tortuous intracellular path, with 
CPEs facilitating transport by disrupting the stratum corneum layer [70,149]. MNAs facilitate 
transdermal permeation by physically bypassing the outer layers of the skin [150]. Very little 
studies have been done on MNA use for the ear, with only inner ear studied [9,151] and no studies 
for use on the TM. 
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For ex vivo testing of transdermal permeation, primate or porcine skin most closely model 
human skin; however, rodent models including guinea pigs are often employed to approximate 
permeability with species-specific permeability highly dependent on the molecule tested [148]. 
For investigation of transtympanic permeability of ciprofloxacin in particular, chinchilla and 
guinea pig models have both been employed [44,68]. 
While there are inherent interspecies differences in TM morphology [144], guinea pigs 
were used in ex vivo transtympanic permeability studies and chinchillas were used for in vivo otitis 
media studies. Both are standard accepted animal models for otic studies with similar TM thickness 
of 10µm in guinea pigs [152] and 15µm in chinchillas [144], compared to 35-150µm thickness in 
humans, dependent on location on the TM [46,144,152]. Guinea pigs were chosen for ex vivo 
studies due to species availability at the primary research site, the University of Pittsburgh, with 
in vivo chinchilla studies performed at the Medical College of Wisconsin using a well-established 
disease model for otitis media [153–155]. Further, guinea pigs are a standard model for middle 
and inner ear pharmacokinetics due to a large middle ear and easy access to the cochlea, while 
chinchillas are ideal for otitis media studies due to similar sensitivity to pathogens and disease 
progression at humans [120], in addition to ease of transbullar injection to inoculate middle ear 
with bacteria without disturbing the TM which was imperative to this study’s focus on intact TMs. 
Haemophilus influenzae was chosen as one of the leading pathogens causing AOM, accounting 
for approximately half of middle ear fluid isolates in children [39,153–155]. 
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3.2 Materials and Methods 
3.2.1 Ex Vivo Transtympanic Permeability 
Dunkin-Hartley guinea pigs (GPs) of both sexes were purchased from Charles River. All 
animal studies were performed with approval from and in accordance with the University of 
Pittsburgh Institutional Animal Care and Use Committee (IACUC) standards. Forty-four GPs were 
used for this study and randomized into three groups: 21 in the negative control group (100µL gel 
with 10mg blank MS), 21 in the test group (100µL with 10mg ciprofloxacin-loaded MS), and 2 in 
the positive control group (0.2% weight/volume ciprofloxacin). Animals were humanely sacrificed 
via anesthesia with 3-5% isoflurane followed by an overdose of intracardiac sodium pentobarbital.  
Ear canals and tympanic membranes were harvested according to guidance by an 
otolaryngology lab technician. The TMs were visually inspected using a dissecting microscope to 
confirm lack of perforation. The ear canals were suspended in 10mL PBS in 50mL beakers with 
the TM parallel to the bottom of the beaker and only the TM surface in contact with the PBS. Due 
to potential for ex vivo tissue degradation, it was necessary to use 3 freshly harvested ears daily for 
the 14-day study duration [147]. 
For the negative control and test groups, 100µL gel mixed with 10mg of MS (blank and 
ciprofloxacin-loaded, respectively) was applied to the TM. Microspheres were aged for days 1-14 
(in triplicate) by suspending in PBS and rotating in a 37°C incubator. Each day, 3 aliquots of MS 
were centrifuged, supernatant removed, and MS resuspended in gel. MS were suspended in gel by 
pipetting gel onto pre-weighed MS and mixing with pipette tip or needle. Drug concentration is 
assumed to be equal with each daily topical administration from a standard 0.2% ciprofloxacin 
drop [58], therefore only one time point with 3 ears was observed for the positive control group. 
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These drops were instilled in the same volume as in humans (250µL) [58], however due to 
physiological differences in ear canal volume between guinea pigs and humans [156–159], 
resulting drug concentration in receiving chamber was scaled down accordingly for comparison. 
To determine drug concentration in the PBS receiving chamber, 1mL was removed and 
frozen daily and all 10mL in the beaker replaced with fresh PBS. All samples were centrifuged at 
3500rpm for 5 minutes, then 500µL of supernatant from each was removed and centrifuged in 
10kDa filters (Amicon Ultra, Merck Millipore, Cork, Ireland) at 8200rpm for 10 minutes. Drug 












3.2.2 In Vivo Acute Otitis Media Disease Model 
Chinchillas of both sexes were purchased from Moulton Chinchilla Ranch (Rochester, 
Minnesota) and all studies were performed with approval from and in accordance with the Medical 
College of Wisconsin IACUC standards. All studies were performed humanely under anesthesia 
and bupivacaine was administered prophylactically to prevent any potential pain associated with 
bacterial infection and subsequent treatment.  
The animals were randomized into four groups: no treatment control, treatment with blank 
MS/gel, treatment with ciprofloxacin MS/gel, treatment with ceftriaxone MS/gel. For MS/gel 
groups, MS were mixed with gel as previously described, by pipetting gel onto the MS and mixing 
with pipette tip or needle. One cohort of animals were inoculated with 1.94 x105 CFU/ear non-
typeable Haemophilus influenzae (strain 86-028NP) via transbullar injection and received 
treatment after 24h, with the contralateral ear as internal control. For subsequent studies, all 
animals were inoculated and treated in both ears 72h after inoculation. Previous studies by other 
groups have also treated animals 72h after inoculation [68,69]. After infection was allowed to 
develop, tympanic membranes were imaged with MedRx otoscope (Largo, FL) and gel/MS was 
instilled to treatment groups using a 1mL syringe with 18G needle. At time points including days 
1, 3, 7, and 14 post-treatment, n=3 animals (for the first cohort) or n=2 animals (for the subsequent 
two cohorts) per group were sacrificed and TMs imaged. 
After sacrifice, the bullae were dissected, visually inspected, and imaged. The middle ear 
effusion and biofilm mass were collected when present. The middle ear lavage was performed 
using 1ml sterile PBS. The effusion/biofilm and lavage were combined to enumerate total viable 
bacteria by plating and presented as CFU/ear. This study was performed with two different gel/MS 
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instillation conditions: 1) 10mg MS/100μL gel; 100μL instilled per ear and 2) 15mg MS/100μL 
gel; 200μL instilled per ear. 
3.2.3 Histopathology 
Following sacrifice of the chinchilla cohorts treated 72h post-infection, the bullae were 
excised and fixed in 10% formalin. TMs were then carefully excised, dehydrated overnight in 70% 
ethanol, embedded in paraffin, sectioned in 5µm thick sections, and stained with hematoxylin and 
eosin (H&E). Paraffin histology was performed by the Tissue Culture & Histology Module within 
the University of Pittsburgh Department of Ophthalmology. Stained sections were imaged and 
evaluated using light microscopy (Leica Microsystems DM2500) with digital microscope camera 
(Leica Microsystems DFC295) by a blinded technician, with group/cohort masked prior to 
evaluation. 
3.2.4 Statistical Analysis 
Ex vivo transtympanic concentrations are represented as average ± standard deviation for 
n=3 samples per time point. Bacterial counts from in vivo efficacy studies were analyzed using 
Kruskal-Wallis test with Dunn’s post-hoc testing to compare each time point within treatment 
groups. Statistical analyses were performed using GraphPad Prism software (San Diego, CA).  
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3.3 Results 
3.3.1 Ex Vivo Transtympanic Permeability 
Ex vivo studies indicate antibiotic can permeate across the tympanic membrane to the 
middle ear space without the use of potentially harmful chemical permeation enhancers (Figure 
17). The standard topical 0.2% ciprofloxacin drops were applied in the same volume as they are 
typically applied in humans – 2 drops twice daily [58]. Due to size difference between guinea pig 
[156] and human [157–159] ears, concentration of ciprofloxacin in the receiving chamber due to 
treatment with these drops was scaled down by a factor of 3 to closer approximate physiological 
conditions. Dose of gel/MS drop can also be increased in humans as human ear canal volume is 







Figure 17: Ex vivo permeability of ciprofloxacin. Ex vivo permeability results showing transtympanic 
ciprofloxacin (CIP) release from gel-MS system and standard twice-daily topical drops (0.2% CIP), scaled to guinea 
pig ear canal volume compared to human ear canal volume. Error bars represent the mean ± standard deviation for 
n=3 ears per time point. 
 
3.3.2 In Vivo Bacterial Counts 
Most groups receiving no treatment (CTL) and treatment with blank MS/gel resulted in 
persistent bacterial infection throughout the study, confirming negative controls have no effect on 
bacterial clearance as expected for the disease model. For the cohort treated with 10mg/100µL gel 
24h after inoculation with H. influenzae (Figure 18), CIP MS/gel treatment resulted in significantly 
decreased bacterial count at Days 7 and 14 post-treatment, with complete clearance observed at 
Day 14. CFX MS/gel treatment resulted in significantly decreased infection after 7 days of 
treatment, with a recurrence of infection by Day 14. No significant decrease in bacteria was 
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19). While infection persisted in all groups, the no treatment control group saw a significant 
decrease in bacterial infection by Day 14 post-treatment. For the subsequent cohort, treatment was 
increased to 30mg MS/200µL gel accordingly. In this final cohort (Figure 20), significant decrease 
in bacterial infection was observed by Day 7 post-treatment in blank MS/gel group and between 
Day 3 and 7 in CIP MS/gel group; however, there was no significant difference between Day 1 





Figure 18: Colony forming units (CFU) of H. influenzae in chinchilla middle ear after treatment 24h post-
inoculation with 10mg MS/100µL gel containing ciprofloxacin (CIP), ceftriaxone (CFX), blank, or no 
treatment control (CTL). Bacterial counts were deterimined upon sacrifice at days 3, 7, and 14 post-treatment. 
Significance (*p<0.05)  was determined using Kruskal-Wallis and Dunn’s post hoc testing. Significantly decreased 
bacterial counts were observed on Day 7 and Day 14 compared to Day 1 in the CIP MS/gel group and Day 7 
compared to Day 1 in the CFX MS/gel group. Error bars represent mean ± standard deviation for n=9 samples in 




























Figure 19: Colony forming units (CFU) of H. influenzae in chinchilla middle ear after treatment 72h post-
inoculation with 10mg MS/100µL gel containing ciprofloxacin (CIP), ceftriaxone (CFX), blank, or no 
treatment control (CTL). Bacterial counts were deterimined upon sacrifice at days 1, 3, 7, and 14 post-treatment. 
Significance (*p<0.05)  was determined using Kruskal-Wallis and Dunn’s post hoc testing and was only observed 




























Figure 20: Colony forming units (CFU) of H. influenzae in chinchilla middle ear after treatment 72h post-
inoculation with 30mg MS/200µL gel containing ciprofloxacin (CIP), ceftriaxone (CFX), blank, or no 
treatment control (CTL). Bacterial counts were deterimined upon sacrifice at days 1, 3, and 7 post-treatment. 
Significance (*p<0.05)  was determined using Kruskal-Wallis and Dunn’s post hoc testing. Bacterial counts were 
significantly decreased on Day 7 compared to Day 1 in the Blank MS/gel group. In the CIP MS/gel group, bacterial 
counts significantly increased from Day 1 to Day 3 and decreased from Day 3 to Day 7.  Error bars represent mean ± 
standard deviation for n=4 samples. 
3.3.3 Histopathology 
H&E stained sections of excised TMs (Figure 21) indicate generally benign tissue response 
to treatment with MS/gel, with similar anatomy to previously reported otitis media chinchilla 
studies [57,68,69,144]. Significant edema is present in the interstitial layer of the control, untreated 
tissue (Figure 21C), as expected for inflammation inherent to OM. Enlargement in the interstitial 
layer is also present but less prominent in the gel/MS treated groups (Figure 21D-F), with all tissue 


























analysis is warranted for material-specific tissue response in future studies. Retention of gel/MS 




Figure 21: In vivo gel/microsphere (MS) placement and histopathology. Representative images of chinchilla 
tympanic membrane A) before and B) after gel/MS instillation. Representative hematoxylin and eosin (H&E)-
stained sections of excised TMs representing non-treated control (CTL) and TMs treated with blank MS/gel, CIP 
MS/gel, and CFX MS/gel (C-F) imaged using light microscopy. Scale bar = 20µm. 
A B 
CTL C Blank D 




Figure 22: Gel/microsphere drop, indicated by red arrow, viewed through reverse side of chinchilla tympanic 
membrane during tissue dissection post-sacrifice during in vivo otitis media disease model study. 
3.4 Discussion 
To supplement in vitro release data which suggested sufficient drug release to treat acute 
otitis media, an ex vivo study of transtympanic permeability also indicates that antibiotic released 
from MS/gel system can permeate across the TM without the use of chemical permeation 
enhancers. Because this study used healthy (not infected) tissue ex vivo, permeability is expected 
to be comparable in infected ears in vivo and clinically due to inflammation inherent to AOM 
[46,160]. Transtympanic permeability of ceftriaxone due to treatment with ceftriaxone-loaded 
MS/gel was not tested. Due to similarity in drug release kinetics and molecular weight (MW = 
554.48 and 331.35g/mol for ceftriaxone and ciprofloxacin, respectively), ceftriaxone release from 
MS is expected to permeate the TM as well. While these studies are not able to account for the 
myriad of complexities in diseased human tissues, including inflammation and increased thickness 
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of TM and inner mucosal layer, our results suggest that sustained, localized delivery from our drug 
delivery system is possible. Future studies can investigate permeability further with the use of 
Franz cell diffusion chambers [145,161]. 
In vivo efficacy studies in a chinchilla model of otitis media resulted in significantly 
decreased infection due to treatment 24h after inoculation (Figure 18) with CIP MS/gel, indicating 
ability of the drug delivery system to treat infection in vivo when treatment occurs at early time 
points after bacterial infection. We hypothesize that recurrence of infection by Day 14 after 
treatment with CFX MS/gel was due to the release kinetics of CFX from MS, where the burst 
release and subsequent linear release were effective in clearing bacteria but lower antibiotic 
concentrations at later time points allowed for remaining bacteria to redevelop infection. Most of 
the negative control groups had no effect on bacterial clearance, as expected for this disease model; 
however, acute otitis media in humans often clears up on its own [42], as observed by significantly 
decreased, but not fully cleared, bacterial infection in one no treatment group (Figure 19) and one 
blank MS/gel treatment group (Figure 20). In cohorts treated 72h after bacterial inoculation, visual 
observation confirmed presence of biofilm in the middle ear, potentially contributing to inability 
of antibiotics to clear infection [10,54–56]. 
Due to this observation, the subsequent cohort was treated with increased concentration of 
MS in gel and increased overall volume of materials applied to 30mg MS/200µL. However, 
bacterial infection and biofilm formation were persistent even with this increased treatment. While 
concentration of MS in gel was maximized, overall volume of treatment and/or loading of drug in 
microspheres can be increased further to maximize permeation of antibiotic across TM, as 
confirmed by results in ex vivo transtympanic permeation (Figure 17) and ABR (Figure 15) studies. 
Further, high variability was observed in both control and treatment groups, as indicated by large 
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standard deviations and recurrence of bacterial infection at later time points after decrease at earlier 
time points. The in vivo results also suggest that variability in the disease model may be decreased 
by separating animals into groups with or without biofilm formation for treatment with CFX or 
CIP, respectively. Additionally, there are some limitations to these in vivo studies as clinical course 
in humans cannot be extrapolated in animals due to highly variable disease development and 
progression in animals, with potential for the disease to not develop, to be self-limited, or to 
become systemic. 
While the gel/MS drop can be removed easily from the eye [38] at the end of treatment 
duration, further investigation is necessary to determine the most effective removal system in a 
human ear model. Chinchilla ears are physiologically similar to human ears therefore they are a 
standard model for otic studies [69,120,162], however there are inherent species-specific 
differences in the physiology including external ear canals that are more tortuous than human 
external ear canals, so removal of the gel was not investigated in the chinchilla in vivo studies 
described herein.  
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4.0 Development and Testing of a Topical Controlled Release System to Encapsulate and 
Release Stem Cell Secretome 
4.1 Introduction 
To address the problem of wound healing of large or chronic TM perforations, growth 
factor and stem cell-based treatments have been investigated, particularly the use of FGF-2 and 
mesenchymal stem cells [79,103–107,109,112–114]. Due to the in-air suspension of TM tissue, 
injection of stem cells or scaffold materials prone to evaporative drying would likely not sustain 
cell viability long enough for healing to occur [163]. This may partially explain the lack of studies 
of MSC transplantation for TM healing [106,111,114] and the need for complex, bioprinted 
scaffolds for cell therapy [109]. Cell therapy also presents logistical and regulatory hurdles 
including scale-up and distribution [164,165]. Modified phospholipid vesicles are one alternative 
[166] but still lack potentially significant, cell-mimetic qualities such as gradient-based release and 
co-factor secretion. 
Interestingly, it has been shown that the regenerative features of MSCs can be mediated by 
secreted paracrine factors independent of cell contact. These factors can be found in cell culture 
media conditioned by proliferating MSCs, and several groups have indeed demonstrated that the 
secretome or conditioned media (CM) from bone marrow MSC cultures possess many of the same 
properties as MSCs themselves in vivo [165,167,168]. These results seem to implicate a very 
significant regenerative role for the paracrine/soluble factors released by MSCs, without the need 
for true cell therapy. 
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Processing of MSC secretome has previously been optimized for encapsulation within 
hydrolytically-degradable polymer microspheres as a substitute for MSCs in tissue engineered 
vascular grafts. These microspheres offer the ability to sustain a gradient-like delivery of 
encapsulated material for an extended period of time from a single, localized dose [57,121,169]. 
Diffusion of proteins after near-zero order release rates from bulk-degrading matrices has been 
shown to result in gradient-like release patterns in vivo [170–172], which is a pattern characteristic 
of many wound healing applications [117]. Another important feature of these methods is the 
ability to encapsulate most or all secreted soluble factors and shed vesicles in the microspheres. 
4.2 Materials and Methods 
All materials were obtained from Sigma-Aldrich (St Louis, MO) unless otherwise noted. 
4.2.1 Mesenchymal Stem Cell Conditioned Media Preparation 
Adipose derived mesenchymal stem cells (MSCs) (RoosterBio Inc.) were cultured in T175 
flasks in RoosterNourish MSC media. Source donors were adults under 45 years old to avoid 
potential deficits in MSC from more elderly patients [173–175]. Batches from two different source 
donors were used and subsequently will be referred to as Batch 1 and Batch 2. When flasks reached 
~70% confluency, 20 mL of fresh media was added and cells were allowed to culture for 48 hours. 
The media was removed and centrifuged at 1200g for 5 minutes to remove any cell debris, flash 
frozen, and stored at -20°C. Remaining cells were subcultured and the process repeated until 
passage 3. Conditioned media (CM) was then filtered in 10kDa filter tubes (Amicon Ultra, 
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MilliporeSigma, Burlingame, MA), frozen, lyophilized, and reconstituted in 450µL DI water. 
Growth factor concentration in two different batches of conditioned media was quantified using 
both MicroBCA Protein Assay and Invitrogen Human FGF ELISA kits (Thermo Fisher Scientific, 
Waltham, MA). Contribution from extracellular vesicles was quantified by incubating CM with 
Pierce RIPA lysis buffer (Thermo Fisher Scientific, Rockford, IL) in a 1:7 ratio for 10 mins at 
37°C. 
4.2.2 Double and Single Emulsion CM-loaded MS Formulations  
CM-loaded microspheres were prepared using a W/O/W double emulsion procedure: 
200mg PLGA (MW 24-38 kDa; viscosity 0.32-0.44dL/g or MW 38-54kDa; viscosity 0.56-
0.6dL/g) were dissolved in 4mL dichloromethane to which 200µL of reconstituted CM in 4.5mL 
DI water was added [38,121,132]. This reconstituted CM is a 1:10 dilution of the CM processed 
as described above. MS fabricated with 24-38kDa MW PLGA will be henceforth referred to as 
MS 503 and MS fabricated with 38-54kDa MW PLGA will be referred to as MS 504. The 
dissolved drug and polymer mixture were sonicated for 10 seconds at 30% amplitude (EpiShear 
Probe Sonicator, Active Motif, Carlsbad, CA) followed by homogenization in 60mL of 2% PVA 
(Polysciences, Warrington, PA) for 1 minute at 7000rpm (Silverson L5M-A, East Longmeadow, 
MA). The resulting emulsion was added to 80mL of 1% PVA and stirred at 600rpm for 3 hours. 
Blank MS were fabricated using the same methods, with DI water alone substituted for CM 
reconstituted in DI water. MS were washed 4 times by centrifugation, resuspended in deionized 
(DI) water, flash frozen in liquid nitrogen, and lyophilized for 48-72 hours (Benchtop Pro, SP 
Scientific, Warminster, PA). 
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Salt-balanced formulations were fabricated using the above methods and with an 
appropriate amount of NaCl added to PVA to balance the osmolality of the ceftriaxone solution. 
A double emulsion formulation was also fabricated using 4mL ethyl acetate (EtAc) as organic 
solvent instead of dichloromethane [176]. 
Single emulsion oil-in-oil formulation was fabricated for MS 503 using 200µL CM 
reconstituted in DMSO added to 200mg PLGA dissolved in 4mL dichloromethane. This mixture 
was homogenized at 7000rpm and subsequent steps for precipitation, lyophilization, and washing 
as described above. Blank MS were fabricated using the same methods, with DMSO alone 
substituted for ceftriaxone dissolved in DMSO. 
4.2.3 CM-loaded MS Morphology Characterizations 
Size, shape, porosity, and drug loading and release were characterized for each set of MS 
prepared. Scanning electron microscopy (SEM) was used to examine shape and morphology of all 
MS formulations (JEOL JSM 6335F, Peabody, MA). MS diameter was quantified by volume 
impedance measurements with mean and standard deviation determined for n=10,000 MS per 
sample (Multisizer, Beckman Coulter, Brea, CA). Density of MS was determined via a 
measurement device custom-made using a 1mL syringe (Figure 3). A known mass, approximately 
20-40mg, of MS was added and MS packed by pushing down on the plunger, allowing for volume 
to be determined and density calculated from the known mass and volume.  
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4.2.4 In Vitro Release from CM-loaded MS 
In vitro release kinetics were determined using 10mg of MS suspended in 500mL 
phosphate buffered saline (PBS) and continuously rotated at 37ºC. The supernatant was removed 
via centrifugation every 24 hours and replaced with fresh PBS. For each formulation, total loading 
was taken to be cumulative drug release when all MS were fully degraded and release was 
exhausted. 
Total protein in the CM MS supernatant was quantified using a MicroBCA Protein Assay 
kit (Thermo Fisher Scientific, Rockford, IL). In brief, a working reagent was prepared according 
to kit instructions and 150µL of working reagent was added to each well of a 96-well plate 
containing 150µL of sample. After 2h incubation at 37°C, UV/Vis absorbance measures were 
determined at 562nm (SoftMax Pro 5, Molecular Devices, Sunnyvale, CA), with background 
signal from blank MS subtracted from each measurement and regressed against the standard curve. 
A standard curve was determined using bovine serum albumin (BSA) for the range 0.5-40µg/mL. 
FGF-2 concentration was quantified using a Human FGF ELISA kit (Invitrogen, Carlsbad, CA). 
Contribution from extracellular vesicles in releasates were lysed using the same lysis buffer 
procedure described above prior to analysis via MicroBCA and ELISA kits. 
4.2.5 Cytotoxicity Assays 
Cell viability in the presence of conditioned media and CM-loaded microspheres was 
analyzed by MTT assay alone, using the same methods as described above. Studies were carried 
out using, ~3,000 human primary dermal keratinocyte cells/well plated in 96 well plates and 
incubated in 200µL Dermal Cell Basal Medium with Keratinocyte Growth Kit (ATCC) for 24h at 
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37°C with 5% CO2 to achieve a monolayer. Cells with medium only were used as the positive 
control for viability in both assays and cells incubated with 70% methanol for 5-10mins prior to 
each assay were used as a negative control, per kit instructions. Test groups included 100µL basal 
medium and 100µL test material: PBS, conditioned medium, 1mg blank MS, 1mg CM MS, blank 
MS releasate, CM MS releasate. Releasates were collected via the same methods as described 
above, with Day 2 releasates used for this study to most accurately represent 24h of release within 
the linear region of total protein release. Once a monolayer of cells was achieved, treatment groups 
were applied and incubated for an additional 24h. Background signal from MS was also accounted 
for by applying 1mg MS in 200µL basal medium to wells with no cells.  MTT assay was performed 
by additional incubation for 4h with 10µL MTT stock solution, followed by incubation for 10mins 
with 50µL DMSO, and absorbance determined in each well via spectrophotometry at 540nm. 
Percent viability was determined by normalizing to 100% viability in the positive control group. 
4.2.6 Scratch Wound Proliferation Assays 
Scratch wound assay methods were adapted from Walter et al 2010 [177]. Human primary 
epidermal keratinocytes were incubated in Dermal Cell Basal Medium with Keratinocyte Growth 
Kit at 37°C with 5% CO2 until flasks reach 70-80% confluency, then transferred to 24-well plate 
at a density of ~65,000 cells/well. Cells were incubated for 24-48h in 1mL basal medium until a 
confluent monolayer was achieved. A vertical scratch was accomplished using a 1000µL pipette 
tip and wells were rinsed 1-2 times with medium to remove any dislodged cells. Scratch wounds 
were then immediately treated, in quadruplicate, with a) 1mL basal medium, b) 1mL MSC 
conditioned media, c) blank MS 503 releasates, d) blank MS 504 releasates, e) CM MS 503 
releasates, or f) CM MS 504 releasates.  
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MSC CM and MS releasates were prepared with 30mg MS suspended in 1mL basal 
medium and rotated at 37°C for 24h prior to centrifugation and filtration at 8200rpm for 30mins 
in 10kDa ultra centrifugal filters (Amicon, MilliporeSigma, Cork, Ireland). MS mass for release 
was scaled up from 10mg/500µL PBS to account for protein concentration lost to non-specific 
adsorption in filtration step (Figure 23). 
Images were collected at time points of 0, 6, 12, 24, and 48h after treatment with inverted 
microscope at 10x magnification (Leica Microsystems DMi1, Buffalo Grove, IL) and digital 
camera (Canon Powershot G7X Mark II, Tokyo, Japan). Images were analyzed using ImageJ 
software with MRI Wound Healing Tool to determine scratch wound area at each time point, with 




Figure 23: Conditioned media-loaded microphere (MS) releasate scaling for scratch wound proliferation 
assays. Releasates were scaled up to account for protein concentration lost to non-specific adsorption during 








































4.2.7 Statistical Analysis 
Data for in vitro release assays, MS density, and cytotoxicity testing are represented as 
average ± standard deviation for at least n=3 samples. Volume impedance measurements of MS 
diameter are represented as average ± standard deviation for n=10,000 particles per sample. 
Student’s t-test was used to analyze increases in total protein and FGF-2 concentrations due to 
lysis of extracellular vesicles. Wound healing percentages in scratch assay studies were analyzed 
using Student’s t-test comparing scratch wounds treated with unconditioned to conditioned 
medium and blank to CM-loaded MS releasates at each time point. All statistical analyses were 
performed using GraphPad Prism software (San Diego, CA).  
4.3 Results 
4.3.1 CM-loaded MS Release Profiles 
Concentrations in MS releasates were quantified using a bovine serum albumin standard 
curve (Figure 24). Standard double emulsion formulations exhibited 38% burst release followed 
by 11 days of approximately linear release and 66% burst release followed by 21 days of 
approximately linear release for CM MS 503 and CM MS 504 respectively (Figure 24). Single 
emulsion was also used to fabricate CM MS 503, resulting in greatest overall release magnitude 
over 15 days and highest burst release of 86% (Figure 25). Release assays were carried out for 11, 









Figure 25: In vitro total protein release from 10mg of double and single emulsion CM-loaded microsphere 
(MS) formulations. Release assay was carried out until all MS were degraded, resulting in 11, 21, and 15 days of 
release from CM MS 503, CM MS 504, and CM MS 503 single emulsion, respectively. Error bars represent the 
mean ± standard deviation for n=3 samples. 
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Salt-balanced MS resulted in 21 days of release for both polymers but higher burst release 
of 79% and 68% for salt-balanced CM MS 503 and CM MS 504, respectively (Figure 26). MS 
fabricated with ethyl acetate as organic solvent resulted in high burst release as well – 70% and 
78% for CM MS 503 EtAc and CM MS 504 EtAc, respectively – but MS degraded after 8 days 
(Figure 27).  
Standard double emulsion CM MS 503 and CM MS 504 were used for subsequent studies. 
While most formulations tested provided similar overall release magnitudes of 20-40µg, these 
formulations were able to most closely achieve the desired 21-day release profile while minimizing 
burst release, therefore providing the most continuous release of MSC CM. While CM MS 503 
did not achieve the 21-day release duration, it had the lowest burst release and therefore the most 




Figure 26: In vitro total protein release from 10mg of salt-balanced double emulsion CM-loaded microsphere 





























Figure 27: In vitro total protein release from 10mg of double emulsion CM-loaded microsphere formulations 
with ethyl acetate as organic solvent. Error bars represent the mean ± standard deviation for n=3 samples. 
 
Concentration of FGF-2 was determined using the standard curve shown in Figure 28. 
FGF-2 ELISA results indicated a burst of ~65.5% or 135.3 ± 51.3pg on Day 1 followed by 15 days 
of release, yielding a cumulative 206.5 ± 14.3pg of FGF-2 released from 10mg of CM MS 504 
(Figure 29). FGF-2 day 1 burst release is consistent with total protein day 1 burst release of 66% 
shown in (Figure 25). While CM MS 504 can release for 21 days before they fully degrade, FGF-




























Figure 28: FGF-2 standard curve determined via spectrophotometric FGF-2 ELISA. 
 
 
Figure 29: Cumulative in vitro FGF-2 release from 10mg of double emulsion CM MS 504. FGF-2 release was 
observed for 15 days, although it takes Error bars represent the mean ± standard deviation for n=3 samples. 
 


























































4.3.2 Contribution from Extracellular Vesicles 
Overall magnitude of total protein concentration in raw and lysed CM from Batch 1 was 
of the same magnitude between passages 1-7. For each passage, lysis resulted in approximately 
fourfold increase in total protein concentration due to EV contribution (Figure 30). Passages 1 and 
2 of Batch 1 were compared to passages 1 and 2 of Batch 2 (Figure 21). While lysis of EVs in 
Batch 2 CM resulted in approximately fourfold increase in total protein concentration as well, 
overall magnitude of total protein in both raw and lysed samples are 7-8 times higher in Batch 2 
than Batch 1. MS were therefore fabricated using conditioned media from Batch 2 to maximize 




Figure 30: Total protein concentration in raw and lysed conditioned media from passages 1-7 of CM Batch 1. 
Lysis results in fourfold increase in total protein concentration, indicating significant contribution from extracellular 
vesicles. Passage number did not have an effect on magnitude of total protein concentration. Significance (*p<0.05) 





































Figure 31: Total protein concentration in raw and lysed conditioned media from passages 1 and 2 of CM 
Batch 1 compared to CM Batch 2. Batches 1 and 2 are from two different source donors. Lysis resulted in fourfold 
increase (*p<0.05) in total protein concentration due to extracellular vesicle contribution in both batches, however 
overall total protein magnitude in both raw and lysed samples are 7-8 times greater (*p<0.05) in Batch 2 compared 
to Batch 1. Significance was determined using Student’s t-tests. Error bars represent the mean ± standard deviation 
for n=3 samples. 
 
FGF-2 concentration in Batch 1 CM was compared to FGF concentration in CM MS 503 
fabricated using Batch 1 CM. While lysis of CM resulted in 2.4-fold increase in FGF concentration, 
contribution to FGF-2 concentration was increased by 89-fold due to lysis of EVs in Day 1 CM 
MS releasates (Figure 32), possibly indicating preferential encapsulation of EVs compared to free 
growth factors. In Day 1 releasates from MS fabricated using Batch 2 CM, 27% and 12.6% of 
cumulative total protein release from CM MS 503 and CM MS 504, respectively, is contained in 











































Figure 32: FGF-2 concentration in raw and lysed Batch 1 conditioned media compared to Batch 1 CM-loaded 
MS releasates on Day 1. Batches are from different source donors. Lysis resulted in 2.4-fold and 89-fold increase in 
FGF-2 concentration in conditioned media and CM MS releasates, respectively, suggesting preferential 
encapsulation of extracellular vesicles over free FGF-2. These are both significant (*p<0.05) increases as 






































Figure 33: Extracellular vesicle (EV) contribution to total protein concentration in Batch 2 CM-loaded 
microspheres. Batches are from different source donors. EVs contributed to 27% and 12.6% of cumulative total 
protein release in CM MS 503 and CM MS 504 releasates, suggesting preferential EV encapsulation in MS 
fabricated using lower molecular weight PLGA. Error bars represent the mean ± standard deviation for n=3 samples. 
 
4.3.3 CM-loaded MS Morphology 
Scanning electron microscopy images (Figure 34) confirm spherical morphology of all 
microsphere types. SEM images also allow for visualization of any porosity in the MS, with 
porosity observed in several conditioned media-loaded and salt-balanced formulations. Visual 
estimates of diameter were confirmed with volume impedance measurements shown in Table 2. 
Lower densities were observed in more porous conditioned-media loaded MS than non-porous 








































Figure 34: Scanning electron microscopy images of A) CM MS 503, B) CM MS 504, C) CM MS 503 single 
emultion, D) CM MS 503 salt-balances, E) CM MS 504 salt-balanced, and F) CM MS 504 with ethyl acetate 
organic solvent. Scale bars = 10µm.  
 
Table 2: Average diameters and densities of blank and conditioned media-loaded microsphere formulations. 
 
Microsphere type Diameter (µm) Density (mg/mL) 
Blank 503 7.85 ± 5.37 776.9 ± 21.6 
Blank 504 6.59 ± 2.20 623.6 ± 54.6 
Conditioned media 503 5.31 ± 1.81 393.3 ± 63.0 
Conditioned media 504 20.42 ± 3.78 419.2 ± 57.8 
A B C 
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4.3.4 Cytotoxicity Due to CM-loaded MS and Releasates 
Acceptable levels of cytotoxicity following 24h of treatment with conditioned media, blank 





Figure 35: Cytotoxicity of conditioned media, microspheres, and releasates. MTT cell viability assay suggests 
approximately acceptable levels of cytotoxicity due to 24h application of blank and conditioned media-loaded 
microspheres and releasates to human dermal keratinocytes. Error bars represent mean ± standard deviation for n=3 
samples for releasate groups and n=6 samples for all other groups. Red dashed line indicates minimum 



















4.3.5 Scratch Wound Proliferation 
No significant differences between groups were observed at t=6h. Significantly increased 
(p<0.05) wound healing was observed at t=12h for treatment with conditioned media compared to 
basal media and treatment with CM MS 503 releasates compared to blank MS 503 releasates. 
Treatment with CM MS 503 releasates also resulted in significantly increased (p<0.05) wound 
healing compared to blank MS 503 releasates at t=24h. All scratch wounds were completely healed 
by t=48h. Similar healing rates and lack of cell death further indicate conditioned media and 
releasates from both blank and CM-loaded MS are noncytotoxic. Representative images of scratch 








Figure 36: Scratch wound healing over time. Wound healing percentages at t=6, 12, and 24h after scratch, 
determined by comparing scratch wound area at each time point using ImageJ software. Errors bars represent mean 
± standard deviation for n=4 samples for basal media and n=3 samples for all other groups. Significance (*p<0.05) 
was determined by Student’s t-test. Significant wound healing was observed due to conditioned media compared to 
basal media at t=12h and CM MS 503 releasates compared to blank MS 503 releasates at t=12h and 24h. Similar 
healing rates and lack of cell death indicate conditioned media and MS releasates are noncytotoxic. Inset: 
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Figure 37: Representative digital images of scratch wounds in human primary dermal keratinocytes cultures 
in 24-well plates at t=0, 6, 12, and 24h.  Scratch wounds were incubated with dermal basal media, mesenchymal 
stem cell conditioned media (CM), and releasates from blank and CM-loaded microspheres. Scale bar = 100µm. 
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TM perforation can occur due to infection or trauma, including pressure-induced rupture 
common in active military zones [76,77], with particularly large or chronic perforations resulting 
in persistent, non-healing injury [72]. Those perforations that do heal spontaneously can require 
up to 8 weeks for complete healing [73,74]. Patients can experience further infection, tinnitus, 
vertigo, or loss of hearing during this time, resulting in temporary or permanent negative effect on 
quality of life. Current clinical grafting standards come with the risk of similar side effects and 
patients are often wary of surgical interventions [75,82]. To ameliorate these potentially 
detrimental side effects, recent research has focused on synthetic and naturally-derived grafting 
alternatives [79,80,84–97], including scaffolds delivering growth factors or topical application of 
growth factors relevant to wound healing [79,97–105]. Several of these studies include embryonic 
[106,111] or mesenchymal stem cell therapy [109,112,113], however there are limitations 
associated with cell viability, logistics, and regulation [164,165]. To address these limitations, our 
group developed a PLGA microsphere-based controlled delivery system to encapsulate and deliver 
MSC secretome to chronic/large-scale tympanic membrane perforations. 
A variety of release profiles were achieved due to different fabrication methods, including 
different molecular weight polymers, different organic solvents, double versus single emulsion 
fabrication, and use of salt balance. This variety indicates that the delivery platform can be fairly 
easily modified to produce different release profiles based on therapeutic need for particular 
conditions, including protein delivery for tissue engineering applications [7,13,19,176]. However, 
the target release profile maximized the magnitude of release while also maximizing release 
duration and minimizing burst release to provide mostly continuous release for the full treatment 
duration. 
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Higher molecular weight PLGA (MS 504) was used to increase microsphere diameter and 
slow degradation rate to extend treatment duration to 21 days while lower molecular weight PLGA 
(MS 503) was used for shorter treatment duration of 11 days while increasing overall magnitude 
of release [13]. Observed MS diameters and densities are consistent with previously observed 
ranges for similar microsphere formulations developed by this group [121,132]. Organic solvent 
was adjusted as an effort to improve protein stability and encapsulation [176], however MS 
fabricated using ethyl acetate degraded much faster than those fabricated with DCM, which may 
be due to solvent extraction rate and provides an avenue to investigate further for future release 
profile tuning [17,178]. Salt balance increased MS porosity, in turn increasing initial burst release 
[13,15,17]. Due to maximization of release duration while minimizing initial burst release, 
standard double emulsion was found to be optimal to produce the desired continuous release 
profile. 
Contribution on Day 1 from EVs to total protein release (Figure 33) made up 27% and 
12.6% for CM MS 503 and CM MS 504, respectively, which may be due to higher molecular 
weight polymer resulting in tighter polymer matrix [14,20], in turn resulting in less EVs loaded 
compared to free protein or EVs trapped in polymer matrix until later time points due to size 
distribution of up to 150nm-1µm dependent on type of EV [179]. Encapsulation and subsequent 
release of EVs from MS can more accurately approximate natural physiological wound healing 
and tissue regeneration, including gradient-like presentation of vesicles and growth factors 
[117,179]. This allows for a biomimetic stem cell-like treatment modality while avoiding 
associated processing, viability, and regulatory issues [164,165]. 
Encapsulation and release of FGF-2 is of particular interest for wound healing of tympanic 
membrane perforations. CM MS were able to burst release 135.3 ± 51.3pg with a cumulative 206.5 
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± 14.3pg of FGF-2 released from 10mg of CM MS 504 (Figure 29). While lysis experiments were 
not performed on all 15 days of FGF-2 release, it can be extrapolated from Figure 31 that a 
significant portion of FGF-2 is bound in extracellular vesicles, with up to 89-fold increase in FGF-
2 due to lysis of EVs on Day 1 resulting in approximately 12ng release. Previous studies have 
demonstrated a range of FGF-2 concentration to be effective for cell proliferation purposes, 
including an in vitro study suggesting 14pg/mm2 in 3D printed fibrin substrates increased cell 
density on the substrates and lengthened time of cell survival [180]. Another study found that 1µg 
of bFGF encapsulated in microspheres and embedded in collagen scaffolds improved cell seeding 
of intestinal smooth muscle cells [181]. For TM perforation healing in particular, studies have 
shown that daily doses of approximately 80ng bFGF improved wound healing time and decreased 
otorrhea [73,182]. These cited values are mostly greater than the release seen in our MS 
formulation. However, further investigation is needed into vesicle shedding on each day of MS 
release and amount of FGF bound in and released from these vesicles. 
Conditioned media alone, conditioned media-loaded MS, blank MS, and MS releasates 
exhibit approximately acceptable levels of cytotoxicity [136–138] following 24h of treatment 
applied to human dermal keratinocytes. These results suggest the microspheres and releasates will 
be biocompatible in vivo.  
Scratch wound proliferation assays further suggest safety of conditioned media and 
conditioned media-loaded microspheres. No detrimental effect is observed due to treatment with 
conditioned media, both blank MS formulations, or both conditioned media-loaded MS 
formulations. Significantly increased proliferation at t=12h due to culturing scratch wound in 
mesenchymal stem cell conditioned media compared to basal media confirms previous results 
reported by Walter et al 2010 [177]. Significantly increased wound healing percentages due to 
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treatment with CM MS 503 releasates compared to blank MS 503 releasates suggest ability of MS 
to facilitate wound healing in vitro. 
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5.0 Demonstration of Tympanic Membrane Healing Over Time In Vivo  
5.1 Introduction 
The use of controlled release has been investigated and shown promise for tissue 
engineering and regenerative medicine, including the release of growth factors and other signaling 
molecules to promote tissue formation and wound healing [7]. Animal models are required for 
determination of preclinical treatment efficacy and safety, as well as to inform further optimization 
of treatment systems [147–149]. Guinea pigs were chosen for TMP studies as they are a standard 
model for otic studies and have easy access to the TM and middle ear [120]. Mouse, rat, and 
chinchilla models have also been used for investigation of TM regeneration, with a variety of 
methods used to create a chronic perforation, including thermal injury, repeat myringotomy, and 
application of inhibitors such as steroids, mitomycin C, and growth factor receptor inhibitors 
[72,88,92,94,109,112,113,183–185].  
For treatment of TM perforations in the guinea pig model described herein, CM MS 504 
were used due to their extended 21-day release profile, which can be seen in Figure 25. 
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5.2 Materials and Methods 
5.2.1 In Vivo Tympanic Membrane Perforation Model 
Animal studies were performed in accordance with the NIH Guide for Care and Use of 
Laboratory Animals and approval by the University of Pittsburgh Institutional Animal Care and 
Use Committee (IACUC). Eighteen male Dunkin-Hartley guinea pigs (GPs) were purchased from 
Charles River at 8 weeks and ~500g. All experimentation was performed under 1-2% isoflurane 
anesthesia. 
Perforation was achieved under anesthesia using an 18G needle. Outer diameter of an 18G 
needle is 0.05in or 1.27mm, which results in a surface area of 1.27mm2 based on the standard 
surface area equation for a circle, 𝐴 = 𝜋𝑟2. Guinea pig TM diameter of approximately 2.5mm 
yields surface area of 4.91mm2, therefore an 18G needle should result in perforation of 
approximately 25% of TM surface area. 
TMs were imaged using video otoendoscopy (Karl Storz vetcam XL with xenon nova 175 
light source, Edgewater, MD) before and after perforation. Mitomycin C (Alfa Aesar, Thermo 
Fisher Scientific, Ward Hill, MA) was applied at a concentration of 0.5mg/mL via gelfoam sponge 
for 5mins after perforation [183,185]. Perforation was followed by twice-daily treatment with 1% 
hydrocortisone (Zymox, PKB Animal Health, Westmont, IL) and 0.2% ciprofloxacin (Sigma 
Aldrich, St. Louis, MO) for 7 days and subsequently 3 undisturbed weeks allowing perforation to 
develop as confirmed by otoendoscopy [184]. For each otoscopic analysis, any ear wax or dried 
blood in the ear canal were cleared using a cotton tipped applicator and/or lavage with sterile water 
as needed. 
 86 
Four weeks after perforation, animals were randomized into one of three treatment groups, 
with n=6 animals per group: no treatment, treatment with daily MSC CM topical drops, treatment 
with CM MS 504/gel. MSC CM was processed as described previously via filtration for 20mins 
at 4000rpm in 3kDa filter tubes (Amicon Ultra, MilliporeSigma, Burlingame, MA) and resulting 
filtrate diluted with DI H2O to approximate release from CM MS. Approximately 100µL of these 
drops were applied at the same time every day for 21 days. For the MS/gel treatment group, 200mg 
MS were mixed with 2mL gel and each animal received 100µL of the mixture administered via 
1mL syringe and 18G x 1” needle. CM MS 504 were fabricated as described in Section 4.2.2. After 
sacrifice via intracardiac sodium pentobarbital under isoflurane anesthesia, TMs were excised, 




Figure 38: Timeline of in vivo tympanic membrane perforation and treatment. 
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Following sacrifice, TMs were excised and after visual inspection, fixed for 24h in 10% 
formalin. TMs were then dehydrated overnight in 70% ethanol, embedded in paraffin, sectioned 
in 5µm thick sections, and stained with hematoxylin and eosin (H&E). Paraffin histology was 
performed by the Histology Module within the McGowan Institute for Regenerative Medicine at 
the University of Pittsburgh, with stained sections imaged and evaluated using light microscopy 
(Leica Microsystems DM2500) and digital microscope camera (Leica Microsystems DFC295) by 
a blinded technician. 
5.3 Results 
5.3.1 Wound Healing of Tympanic Membrane Perforations 
After sacrifice, both left and right TMs were removed from each animal and visually 
inspected as well as photographed to determine presence of perforation or any abnormal 
physiology. All left ears, which had no manipulations or treatment, were pristine as expected. 
Right ears were classified into three categories: 1) absent TMP, normal physiology; 2) absent 
TMP, abnormal physiology, 3) visible TMP. Representative images can be seen in Figure 39.  
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Figure 39: Representative images of tympanic membranes (TMs) post-sacrifice. A) Pristine TM from 
contralateral ear with no manipulations or treatment; B) No perforation but abnormal physiology characterized by 
sagging TM and presence of dried blood; C) small TM perforation (TMP); D) larger TMP. Wound margins are 
outlined in white for each TMP. 
 
In the no treatment group, 2 of 5 ears had small visible TMPs with the remaining 3 having 
absent TMP but abnormal physiology, including sagging rather than tight TM and presence of 
blood or other fluid. In the group treated with daily CM drops, 2 of 5 ears also had visible TMPs, 
however 2 had absent TMPs with normal physiology and 1 had absent TMP with abnormal 
physiology, suggesting increased wound healing due to application of conditioned media. In both 





study early. One animal was in the no treatment group due to an adverse reaction to anesthesia and 
one was removed from the CM drops group due to infection unrelated to treatment.  
In the group treated with CM MS/gel, gel was found inside the bulla, indicating either that 
it was placed through the TMP during instillation or sunk through the perforation into the bulla 
during the treatment duration. Presence of gel physically blocking the TMP from healing may have 
had an adverse effect on wound healing, with 3 of 6 of animals having visible TMP and abnormal 
physiology including gel protruding through the TMP and fluid and cerumen build up. Presence 
of gel on reverse side of TM and healed TM visualized after removal of gel can be seen in Figure 
40. However, 1 animal had absent TMP with normal physiology and 2 animals had absent TMP 
but with some abnormal physiology including fluid and cerumen build up. For this group, all 6 




Figure 40: Conditioned media-loaded microspheres/gel after sacrifice and dissection: A) on reverse side of TM, 






Table 3: Results of tympanic membrane perforation (TMP) in vivo study. Results are displayed as number of 
ears for each observed TM condition post-sacrifice for each treatment group. For no treatment and daily CM 
drops, n=5 animals were analyzed while all n=6 were analyzed for CM MS/gel group due to 2 animals 
removed from the study due to adverse reaction to anesthesia and infection unrelated to treatment. 
 





No treatment 0 3 2 
Daily CM drops 2 1 2 
CM MS/gel 1 2 3 
 
5.3.2 Histopathology 
While the tissue samples for pristine TM and TM with perforation absent and normal 
physiology (Figure 41A-B) where somewhat damaged during dissection and staining, H&E 
staining indicates normal physiology and lack of edema or immune response, comparable to 
previous examinations of healthy guinea pig TMs. TM with absent perforation but abnormal 
physiology (Figure 41C) displays increased edema. TM with visible perforation (Figure 41D) 
displays increased edema as well as enlargement compared to other samples, indicating damage 




Figure 41: Representative images of hemotoxylin and eosin (H&E) stained guinea pig tympanic membranes 
(TMs). Images represent A) pristine TM; B) absent TMP, normal physiology; C) absent TMP, abnormal 
physiology; and D) visible TMP. Scale bars = 200nm. 
5.4 Discussion 
The group that received no treatment resulted in 40% persistent TMP, which agrees with 
previously cited statistics of 6-46% of TMPs being non-healing without treatment [73,74]. The 
remaining 60% displayed abnormal physiology including build-up of fluid, dried blood, and 




daily CM MS drops also resulted in 40% non-healing, only 20% had abnormal physiology and the 
remaining 40% had no visible TMP and normal physiology. These results suggest a positive effect 
on wound healing due to application of conditioned media drops, which is expected due to previous 
studies on growth factor and stem cell treatment exhibiting positive effects on wound healing 
[73,74,102,103,106,112,114]. 
CM MS 504 were chosen for CM MS/gel group study due to their extended 21-day release 
profile (Figure 16). Either during placement or during the treatment duration, all MS/gel systems 
migrated through the TMP into the bulla. In several cases, the gel/MS system was protruding 
through the TMP and physically preventing the wound from healing. This may have also 
contributed to increased fluid and cerumen build up, as abnormal physiology was observed in all 
TMs with TMPs and 33.3% of ears showed no visible TMP but persistent abnormalities. However, 
despite gel/MS migration into the bullae, 16.7% of ears had complete wound healing.  
There were a number of limitations to the guinea pig TMP model described herein that can 
be addressed in future studies. Perforation was achieved using an 18G needle in this study, which 
occasionally resulted in injury to the external ear canal, causing blood and subsequently dried 
blood to confound imaging. Further, this technique may have caused a tear than a distinct TMP. 
To ensure precise placement of the needle, a myringotomy needle attachment can be used in 
conjunction with the otoscope. Further, irrigation and suction attachments can be used to better 
clear ear canal of any ear wax, blood, or moisture that can confound visualization and imaging. 
Myringotomy can also be performed repeatedly over several weeks to ensure TMP becomes 
chronic. Other techniques include injury using thermal cautery and folding of wound edges after 
myringotomy; however, there is some dispute as to the reliability of these methods [184]. 
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Mitomycin C is an antibiotic that prevents cell proliferation and can delay healing but does 
not result in chronic TMP by itself. However, there is evidence that application of higher 
concentrations of mitomycin C for longer periods of time up to 7 days can delay healing but there 
are concerns of ototoxicity associated with high concentrations of mitomycin C [184,185]. The 
study described herein used a relatively high concentration of 0.5mg/mL applied via gelfoam 
sponge for 5mins after perforation. To delay healing duration and closer approximate chronic TMP 
in vivo while minimizing ototoxicity, different concentrations of mitomycin C and application 
durations can be tested. Dexamethasone can also be used topically to delay healing up to 30 days, 
as well as hydrocortisone, which was applied for 7 days in our study but can be extended to 10 
days to make TMP more persistent. Based on previous studies, mitomycin C used in conjunction 
with a steroid results in synergistic effects on delaying TMP healing [184]. 
To determine time-dependent effect of treatment on TM healing, TMs can be imaged 
weekly via otoendoscopy, with MS/gel drop removed to facilitate visualization and replaced with 
fresh gel containing aged MS. To achieve a consistent release profile, MS should be aged for days 
1-21 (n=12 samples of 10mg) by suspending in PBS and rotating in a 37°C incubator. As 
previously described for release assays, these aliquots should be centrifuged and supernatant 
collected every 24h. For each imaging time point, MS can be resuspended in gel after 7 days (n=6 
samples) and 14 days (n=6 samples) and used as replacement MS/gel drop after otoendoscopy. 
In conjunction with otoendoscopic imaging for qualitative assessment of TM wound 
healing, auditory brainstem responses can be used as described previously to confirm TMP due to 
conductive hearing loss as a result of non-intact TM and confirm adequate wound healing 
determined by a renewed capacity to hear using injured ear [143,144,185]. ABRs are also used as 
a test of safety of ototopical treatments based on effect on hearing sensitivity [65,69,145,146]. To 
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more accurately determine positive effect on wound healing due to topical CM drops and CM MS 
treatment, ABRs can be used longitudinally in addition to imaging to track hearing sensitivity after 
myringotomy to induce TMP and during treatment, as well as at a time point some weeks or months 
after treatment to determine long term effects of treatment. 
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6.0 Summary and Future Directions 
6.1 Overall Summary 
The studies described in this dissertation address an unmet need of safe, easy-to-administer, 
and effective topical drug delivery systems to the tympanic membrane and middle ear. This work 
developed a drug delivery platform comprised of hydrolysable polymer microspheres for 
controlled release of various therapeutics and scaled up a previously developed gel for increased 
ease of application and retention of microspheres in situ. This drug delivery system was able to be 
modified during fabrication to encapsulate and release a variety of therapeutics in a variety of 
release profiles, indicating its potential as a delivery platform that can be modified and optimized 
based on therapeutic need for particular conditions. 
These studies demonstrate that the PLGA MS/thermoresponsive gel system is capable of 
encapsulating and subsequently releasing up to 14 days of potentially therapeutically relevant 
levels of two different antibiotics for clearance of bacteria present in acute otitis media. In vitro 
cell viability and bacteria killing studies indicated these materials can be safe for in vivo and 
eventual clinical use while maintaining ability to clear bacteria. Histopathological evaluation 
suggests in vivo safety of the drug delivery system, with further research needed to examine 
material-specific toxicity response. Auditory brainstem responses indicated complete coverage of 
TM and ability to increase volume of material applied to increase therapeutic potential while 
maintaining minimal effect on quality of life due to hearing attenuation during treatment. In vivo 
studies in a chinchilla otitis media disease model demonstrated potential for the novel drug 
delivery system to effectively treat bacterial infection, with room for improvement and 
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optimization of the animal model for future efficacy studies, including accounting for variability 
in the disease model by testing for biofilm presence prior to treatment and determining optimal 
dose and treatment window after bacterial inoculation. 
The PLGA MS are also capable of encapsulating and subsequently releasing MSC 
conditioned media, including free and extracellular vesicle-bound growth factors such as FGF-2 
for up to 21 days. Further investigation is necessary to determine daily vesicle shedding from MS 
and total protein and FGF-2 content in these vesicles. In vitro cell viability testing and scratch 
wound proliferation assays suggest these materials can be safe for in vivo and clinical use and 
indicate wound healing ability. While there were limitations in the TMP animal model, there is 
evidence to suggest CM has a positive impact on wound healing and CM-loaded MS/gel 
placement, with some improvement and refinement of placement and removal techniques, may 
also have a positive effect on wound healing. 
6.2 Summary of Challenges and Limitations 
While promising formulations were developed for delivery of two different antibiotics and 
stem cell conditioned media from PLGA MS, there were a number of challenges and limitations 
in the studies described herein. Firstly, despite mostly acceptable levels of in vitro cytotoxicity, 
several groups resulted in slightly less than 70% cell viability at 24h in culture and several groups 
displayed high variability in percentage of viability. These results, along with previously reported 
studies on biocompatibility of both PLGA-based materials and the loaded therapeutics, suggest in 
vivo biocompatibility of this drug delivery system. However, further studies investigating time and 
concentration dependence may be warranted. Variable results were also noted in histological 
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examination of both chinchilla and guinea pig tissues. In terms of the AOM chinchilla disease 
model study, presence of infection leads to inherent tissue inflammation and confounds the 
histology results. For examination of tissue response to materials alone, materials should be 
applied to healthy animals and histology performed after serial sacrifice at various time points 
during the intended treatment duration. Further, long term in vivo ototoxicity was not investigated. 
This could be achieved using ABR at a chronic time point some weeks after end of treatment 
duration. In particular, ceftriaxone has not been previously used topically therefore topical safety 
must be investigated. 
For scratch wound proliferation assays testing in vitro efficacy of conditioned media and 
CM-loaded MS releasates, a challenge was posed by presence of MS in releasates confounding 
imaging of scratches. This issue was addressed by filtration, however this resulted in decreased 
concentration of total protein in the releasates due to non-specific adsorption to the filters. Release 
was scaled up for total protein after filtration to match original unfiltered release. Effect of filtration 
on FGF concentration in releasates was not investigated. While significant differences in wound 
healing were observed due to CM MS 503 releasates, no significant increases were observed due 
to CM MS 504 releasates compared to blank MS releasates. For these studies, 24-well plates were 
used, which have a surface area of approximately fivefold greater than human TM surface area. 
Therefore, increased wound healing may be seen in smaller surface area due to greater 
concentration of protein localized to the scratch wound. Smaller well plates were not able to be 
used due to difficulty in creating the scratch. Further optimization of a more physiologically 
relevant in vitro scratch wound assay may provide more relevant and repeatable results. 
While ciprofloxacin-loaded and ceftriaxone-loaded MS showed some promise in treatment 
of AOM in vivo, there were challenges with this animal model as well. First, treatment 24h after 
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bacterial inoculation may not have allowed enough time for infection to develop but adjustment to 
treatment 72h after inoculation resulted in persistent biofilm formation. Rather than randomizing 
animals into treatment groups, animals can be tested for presence of bacteria and biofilm formation 
prior to treatment, with animals exhibiting persistent biofilm treated with ceftriaxone-loaded MS 
while those with bacterial infection but no biofilm treated with ciprofloxacin-loaded MS. Another 
challenge included application of the gel/MS system directly onto the TM. An applicator using a 
syringe and bent 18G needle were used to improve application of precise amount of gel/MS to the 
TM, however a more reliable and precise system must be engineered for reliable application in 
animal models, as well as for humans for clinical use. 
There were also challenges associated with the in vivo TMP model in guinea pigs. It was 
difficult to ensure successful TMP using an 18G needle and due to a lack of visualization, the 
needle occasionally injured the external auditory canal prior to perforation, with blood in the canal 
confounding imaging using otoendoscopy and making confirmation of successful TMP difficult. 
Further, dried blood and cerumen in the ear canal confounded confirmation of TMP over time as 
well. One solution to this limitation can be the use of a myringotomy needle attachment to otoscope 
to ensure better visualization during perforation. In addition to otoscopy, weekly ABR experiments 
were originally planned to confirm presence of TMP, as well as to track wound healing over time. 
However, there were time constraints associated with the number of animals that could be tested 
each day and complications from anesthesia resulted in one animal removed from the study. These 
ABR experiments are an important metric of effect of wound healing on hearing sensitivity as well 
as a metric of ototoxicity over time and therefore should be included in future studies with 
improved experimental design accounting for associated time constraints, including performing 
experiments on one group at a time rather than all treatment groups simultaneously. 
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6.3 Future Directions 
Future studies will focus on further microsphere optimization and improvement of the 
disease models, including increased antibiotic delivery and accounting for variability in the otitis 
media model as well as further investigation of best practices for inducing tympanic membrane 
perforation and investigation of time-dependent effect of treatment on wound healing. Future work 
will also investigate incorporation of analgesic into the gel for local pain relief due to AOM 
[146,186–188] and encapsulation of other therapeutics into this drug delivery system for topical 
treatment of other otic conditions. In addition, there is a need for expanded testing of long-term 
ototoxicity due to topical ceftriaxone alone and application of all drug-loaded MS/gel, including 
longitudinal ABR testing to investigate chronic effect on hearing after treatment. Further, clinical 
translation potential can be improved by engineering design of a user-friendly applicator for the 
drug delivery system and investigation of best practices to remove the MS/gel at the end of the 




Quality Control of Brimonidine Tartrate Microsphere and Gel Fabrication for Treatment 
of Glaucoma 
Appendix A.1 Introduction 
Using techniques developed for encapsulation of small molecular weight, water-soluble 
drugs like ciprofloxacin, a natural extension of the work described in this dissertation was to 
investigate encapsulation of similar drugs for other applications, such as the controlled release of 
brimonidine tartrate (BT) for treatment of glaucoma. Ciprofloxacin and BT have similar molecular 
weights of 331.346g/mol and 442.22g/mol, respectively, and are both water-soluble, therefore 
comparable formulation techniques can be used for encapsulation of both molecules. Further, 
standard topical eye drops suffer from some of the same issues as topical ear drops, including low 
permeability and low patient compliance due to high dosing frequency and difficult administration. 
Appendix A.1.1 Glaucoma Severity and Treatment 
Glaucoma, the second leading cause of blindness worldwide, is characterized by increased 
intraocular pressure (IOP) that damages the optic nerve which in turn causes vision impairment 
[38,189]. Treatment typically consists of eye drops applied topically multiple times a day for the 
rest of the patient’s life, a high frequency dosing regimen that, in conjunction with difficulty of 
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administration, results in high levels of non-adherence to the proper treatment regimen. In addition, 
ocular drops suffer from low penetration through the cornea due to blinking, rapid lacrimal fluid 
turnover, and nasolacrimal drainage resulting in short retention times of drops residing on the 
cornea [5,38,121,189,190]. Among the commonly prescribed treatments for glaucoma are 
brimonidine tartrate drops. BT can reduce IOP by decreasing production of aqueous humor and 
also increase uveoscleral outflow. BT has also shown to have neuroprotective effects and lower 
pulmonary and cardiovascular side effects compared to other glaucoma treatments. 
To ameliorate some of the compliance and pre-corneal residence time issues associated 
with standard topical drops, a variety of drug delivery systems have been investigated including 
nanoparticles, microspheres, hydrogels, implants, and ocular inserts [5,189,190]. An ideal topical 
ophthalmic drug delivery system should be easy to administer without causing irritation or 
adversely affecting patient’s vision, decrease dosing frequency, increase pre-corneal retention to 
increase drug penetration and bioavailability, and decrease risk of systemic side effects. To this 
end, previous studies by this group investigated the development of BT-loaded PLGA 
microspheres that can be administered via subconjunctival injection or topically applied via a 
thermoresponsive gel depot [38,121]. 
Appendix A.1.2 Key Factors for Biomedical Translation of Biomaterials 
More generally, some of the key factors for biomaterials to be used in biomedical 
applications include: simple fabrication and processing, biocompatibility (including easy 
metabolization of degradation byproducts of biodegradable materials), sufficient shelf-life for 
prescribed use, and ability to be sterilized without significant mechanical or functional changes 
[8]. 
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Release profiles from polymer microspheres can be modulated by adjusting factors such as 
copolymer ratio, polymer molecular weight, microsphere size, porosity of polymer matrix, and 
drug concentration/dispersion in the microspheres [13–17]. In single and double emulsion 
fabrication methods, surfactants such as poly(vinyl alcohol) (PVA) are used as emulsifiers 
[20,191]. Properties of the surfactant used can affect drug encapsulation and polymer matrix 
porosity [13,15]. For example, altering PVA concentration in fabrication has previously shown to 
affect matrix porosity and in turn modulate initial burst release phase [13,192]. Additionally, 
surfactants have been used to increase solubility and bioavailability of hydrophobic and poorly 
soluble drugs as well as surface functionalization of controlled release systems such as 
nanoparticles to improve circulation [193–196]. For encapsulation of proteins in particular, 
surfactants can stabilize the oil-water interface which is known to cause protein denaturation, 
therefore use of an appropriate surfactant can increase encapsulation efficiency of active proteins 
[191,192].  
For clinical use, biomedical devices and materials must be sterilized to ensure materials do 
not introduce any biological contaminants to patients during treatment. For ease of fabrication, 
final sterilization is preferable to fabrication of materials under sterile conditions [19]. Gamma 
irradiation is frequently used as a sterilization method for PLGA and hydrogel materials and has 
been shown to effectively sterilize the materials without significantly compromising their material 
properties or drug delivery capabilities [175–180]. Other sterilization techniques include ethylene 
oxide and autoclaving, however steam causes degradation of hydrolysable materials and high 
temperatures can adversely affect thermosensitive materials such as the pNIPAAm gel used in our 
studies [19]. Gamma irradiation is effective due to high penetration into the material but can cause 
some structural changes to the polymer and encapsulated drug, particularly proteins, including 
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reducing molecular weight of the polymer which can in turn reduce the duration of the lag phase 
of drug release [13,19]. To ensure retention of desired release profile after sterilization, it is 
important to perform quality control experiments on the materials in addition to endotoxin testing 
to confirm effect of sterilization and lack of structural changes to the materials. 
In addition to quality control of sterility, it is important to investigate long term storage of 
biomaterials, as they should not degrade or deteriorate before their intended use [203]. In addition 
to time scale, storage conditions such as temperature and humidity can affect performance of 
polymer microspheres and gels [204,205]. PLGA microspheres are typically stored at -20°C due 
to lack of mobility of polymer chains and lack of moisture at temperatures below freezing. 
However, to account for patient noncompliance to storage requirements, it is important to 
investigate shelf life of materials at a variety of storage temperatures, including standard 
refrigeration and ambient conditions [204,205]. At high temperatures and/or high humidity, 
accelerated physical aging can occur which can negatively impact shelf life of polymeric materials 
and affect release of encapsulated therapeutics [203,205]. 
Appendix A.2 Materials and Methods 
Materials were obtained from Sigma-Aldrich (St Louis, MO) unless otherwise noted. 
Appendix A.2.1 Brimonidine and Ciprofloxacin-loaded MS Formulations 
BT-loaded MS were fabricated according to previously published methods [31,114]. In 
brief, 200mg PLGA (MW 24-38 kDa; viscosity 0.32-0.44dL/g) were dissolved in 4mL 
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dichloromethane and 250µL of 50mg/mL BT (Santa Cruz Biotechnology, Santa Cruz, CA) was 
added. This mixture was sonicated for 10 seconds at 30% amplitude (EpiShear Probe Sonicator, 
Active Motif, Carlsbad, CA) and then homogenized in 60mL of 2% PVA (Appendix Table 1) for 
1 minute at 7000rpm (Silverson L5M-A, East Longmeadow, MA). The resulting double emulsion 
was added to 80mL of 1% PVA and stirred at 600rpm for 3h. Ciprofloxacin-loaded MS were 
fabricated using the same methods, using 250µL of 100mg/mL ciprofloxacin. Blank MS were 
fabricated by substituting DI water alone for aqueous drug. All MS were washed 4 times by 
centrifugation, resuspended in DI water, flash frozen in liquid nitrogen, and lyophilized for 48-72 
hours (Benchtop Pro, SP Scientific, Warminster, PA). 
Appendix A.2.2 Surfactant Molecular Weight Determination 
To investigate surfactant effect on MS release profiles, molecular weights (MW) of 4% 
PVA solutions were analyzed using size exclusion chromatography (SEC) via gel permeation 
chromatography (GPC) performed by the University of Pittsburgh Department of Chemistry. 
Molecular weights were determined for Polysciences brand PVA lots purchased in 2015 and 2019 
(referred to as PS 2015 and PS 2019) and Alfa Aesar PVA purchased in 2019. A 4% solution of 
each brand of PVA was prepared by dissolving 32g of solid PVA powder in 800mL of DI H2O 









Viscosity (cP) of 
4% PVA in H2O 
% Hydrolysis Year purchased 
Polysciences (PS) 25,000 5.5-6.0 98 2015 
Polysciences (PS) 25,000 5.5-6.0 98 2019 
Alfa Aesar 11,000-31,000 N/A 98-99 2019 
Sigma-Aldrich 31,000-50,000 5.4-6.5 98-99 2019 
Acros 13,000 3.5-3.5 98-98.8 2019 
 
Appendix A.2.3 Fluorescein Isothiocyanate-loaded MS Fabrication 
MS were also fabricated with fluorescein isothiocyanate (FITC) loaded as surrogate drug. 
These MS were fabricated using the above methods with 50:50 lactide:glycolide PLGA with MW 
24-38kDa (viscosity 0.32-0.44dL/g) and MW 38-54kDa (viscosity 0.45-0.60dL/g), 75:25 
lactide:glycolide PLGA (MW 76-115kDa; viscosity 0.71-1.0dL/g), and 85:15 lactide:glycolide 
PLGA (MW 190-240kDa; viscosity 1.3-1.7dL/g). These will subsequently be referred to as FITC 
MS 503, FITC MS 504, FITC MS 756, and FITC MS 858, respectively. FITC MS 503 were 
fabricated using DCM or acetonitrile (ACN) as organic solvent. FITC MS 503 and FITC MS 756 
were also fabricated using single emulsion with FITC dissolved in DMSO. All FITC MS 
formulations incorporated an appropriate amount of salt in PVA to balance osmolality of FITC 
solutions. A summary of these properties can be found in Appendix Table 2. 
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Appendix Table 2: FITC MS fabrication parameters. 
 
Batch name PLGA properties Organic solvent FITC solution 
FITC MS 503 50:50 lactide:glycolide; 
MW 24-38kDa 
DCM 20mg/mL in DI water 
FITC MS 503 ACN 50:50 lactide:glycolide; 
MW 24-38kDa 
ACN 20mg/mL in DI water 
FITC MS 503 DMSO 50:50 lactide:glycolide; 
MW 24-38kDa 
DCM 20mg/mL in DMSO 
FITC MS 504 50:50 lactide:glycolide; 
MW 38-54kDa 
DCM 20mg/mL in DI water 
FITC MS 756 75:25 lactide:glycolide; 
MW 76-115kDa 
DCM 20mg/mL in DI water 
FITC MS 756 DMSO 75:25 lactide:glycolide; 
MW 76-115kDa 
DCM 20mg/mL in DMSO 
FITC MS 858 85:15 lactide:glycolide; 
MW 190-250kDa 




Appendix A.2.4 In Vitro Drug Release Assays 
Drug release from these formulations were quantified as described previously, with 20mg 
BT MS, 10mg ciprofloxacin MS, or 10mg FITC MS suspended in 500mL PBS, rotated at 37°C, 
and supernatant collected daily by centrifugation for 5mins at 3500rpm. BT was quantified by 
UV/Vis absorbance at 320nm and ciprofloxacin was quantified at 246nm. FITC was quantified by 
fluorescence intensity at λex = 460nm and λem = 515nm (SoftMax Pro 5, Molecular Devices, 
Sunnyvale, CA). 
Appendix A.2.5 Thermoresponsive Gel Fabrication 
Gel was fabricated according to previous small-batch methods [31] via free radical 
polymerization of 100mg NIPAAm (Fisher Scientific, Waltham, MA) and 100µL PEG (MW 
~200kDa) in the presence of 2mL of 0.5mg/mL APS and 5 µL TEMED, refrigerated for 24h, and 
washed in DI water at ~40ºC. 
Appendix A.2.6 Material Shelf Stability and Sterilization 
Microspheres and gel were stored at various storage temperatures (Appendix Table 3) for 
1, 3, 6, and 12 months. These time points and temperatures were chosen based on previous studies 
on storage conditions and shelf stability of PLGA MS and gels [204,205]. At these time points, 
properties including microsphere morphology and drug release and gel LCST were tested to 
determine shelf-life stability. Materials were sterilized in 50mL conical Falcon tubes via gamma 
irradiation at 2.5x106cGy at room temperature for 18h. Control and irradiated samples were 
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analyzed for significant differences in endotoxin concentration with Mann Whitney U testing using 
GraphPad Prism Software. 
 
Appendix Table 3: Stability testing storage conditions. 
 
Material Storage temperatures (°C) Storage time (months) Properties 
BT microspheres -20, 4, 25 1, 3, 6, 12 SEM, BT release 
Gel 4, 25, 30 1, 3, 6, 12 LCST 
Appendix A.3 Results 
Appendix A.3.1 Brimonidine and Ciprofloxacin MS Morphology and Release Profiles 
Overall morphology of both BT and ciprofloxacin MS was not changed due to different 
PVA used during fabrication, as observed visually using SEM (Appendix Figure 1 and 2). BT 
concentrations in MS releasates were determined using the standard curve in Appendix Figure 3. 
BT MS fabricated using Sigma-Aldrich and Acros PVA degraded after 24 and 48h in PBS, 
respectively. The original formulation reported in Fedorchak et al 2014 [114] observed an 
approximately 10µg burst release followed by ~2µg/day for 28 days for an overall release 
magnitude of ~60µg. BT MS fabricated using Polysciences 2015 PVA exhibited greater burst 
release but similar release rate. BT MS fabricated using Polysciences 2019 PVA exhibited similar 
burst release (6.43 µg) as the original 2014 formulation but a slower release rate of 0.9µg/day for 
an overall release magnitude of 31.5µg, which is approximately half of the original formulation 
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overall magnitude. BT MS fabricated using Alfa Aesar PVA exhibited the same release rate as the 
PS 2019 PVA formulation but MS degraded after 14 days rather than the full 28-day release 
profile. These release profiles are summarized in Appendix Figure 4 and Appendix Table 4. In 
contrast, while there were some differences between ciprofloxacin release curves, initial burst, 





Appendix Figure 1: Scanning electron microscopy images of brimonidine tartrate microspheres. MS were 
fabricated using A) Polysciences 2015, B) Polysciences 2019, C) Alfa Aesar, D) Sigma-Aldrich, and E) Acros PVA. 




Appendix Figure 2: Scanning electron microscopy images of ciprofloxacin microspheres. MS were fabricated 
using A,B) Polysciences 2015, C) Polysciences 2019, and D) Alfa Aesar PVA. Scale bar = 10µm. 
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Appendix Figure 3: Brimonidine tartrate standard curve determined via spectrophotometry. 
 
 
Appendix Figure 4: Brimonidine tartrate release from 10mg microspheres fabricated using different 
surfactants: Polysciences 2015, Polysciences 2019, and Alfa Aesar. Release assays were carried out until all 
microspheres were degraded: 28 days for both Polysciences lots and 14 days for Alfa Aesar. Error bars represent the 
mean ± standard deviation for n=3 samples. 
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Appendix Table 4: Brimonidine tartrate MS formulations and release parameters. 
 
Parameter Original 2014 PS 2015 PS 2019 Alfa Aesar 
Initial burst 
release (µg) 
~20 35.3 6.43 1.05 
Overall release 
magnitude (µg) 
~60 86.9 31.5 13.03 
Release rate 
(µg/day) 




Appendix Figure 5: Ciprofloxacin release from 10mg microspheres fabricated using different surfactants: 
Polysciences 2015, Polysciences 2019, and Alfa Aesar. PS 2015_1 and PS 2015_2 refer to two different batches of 
ciprofloxacin-loaded MS fabricated with Polysciences 2015 PVA and tested on different dates. Error bars represent 
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Appendix A.3.2 Surfactant Molecular Weights 
A standard curve for size exclusion chromatography was determined for a retention time 
range of 4.94-8.18mins corresponding to a molecular weight range of 1,350-670,000Da (Appendix 
Figure 6). For each lot of PVA, peaks were determined within the detection range at approximately 
6-6.5mins (Appendix Figure 7). These peaks correspond to the PVA. For PS 2015, a peak at 6.29 
mins corresponds to 66,000Da. For PS 2019, peaks at 6.21 and 6.74mins correspond to 76,000 and 
30,000Da, respectively. For Alfa Aesar, a peak at 6.38 mins corresponds to 57,000Da. These 
determined molecular weights are all greater than listed molecular weights of 25,000 Da for both 
Polysciences lots and 11,000-31,000Da for Alfa Aesar (Appendix Table 5). 
Peaks above the detection range are less than 1,350Da and may correspond to vinyl 
monomer, which has a molecular weight of 44.05Da. Further investigation is needed to determine 






Appendix Figure 6: Standard curve for size exclusion chromatography determined at absorbance of 280nm. 
 
Appendix Table 5: Listed and experimentally-determined molecular weights of different PVA lots. 
 
Brand, year purchased Listed MW (Da) Experimental MW (Da) 
Polysciences (PS), 2015 25,000 66,000 
Polysciences (PS), 2019 25,000 76,000; 30,000 
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Appendix Figure 7: Size exclusion chromatography spectra for Polysciences 2015, Polysciences 2019, and 
Alfa Aesar PVA. Detection range of 4.94 – 8.18 minutes is indicated by red dotted lines. 
 
Appendix A.3.3 FITC MS Morphology and Release Profiles 
FITC MS morphology was overall spherical and non-porous, with the exception of MS 
fabricated using ACN as organic solvent, which resulted in large size distribution and distorted 
morphology (Appendix Figure 8). Release profiles were determining using the standard curve in 
Appendix Figure 9. FITC MS fabricated using different polymers, organic solvents, and double 
versus single emulsion resulted in differing release curves as shown in Appendix Figures 10 and 
11. Standard double emulsion fabrication using 503 or 503 PLGA did not result in large differences 
in release profile, with MS 503 exhibiting slightly greater initial burst and overall magnitude of 
release. FITC 503 ACN and DMSO exhibited similar burst and release curve as well, however 
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release profiles. FITC MS 756 and 858, those fabricated with higher ratio of lactide to glycolide 
in the PLGA, exhibited lower burst and overall magnitude of release, with the lowest release 
correlated with the highest ratio of lactide in FITC 858 MS. FITC MS 756 DMSO exhibited a 





Appendix Figure 8: Scanning electron microscopy images of FITC microspheres. Representive images are 




Appendix Figure 9: Fluorescein standard curve determined using spectrophotometry. 
 




























Appendix Figure 10: FITC release from 10mg of 503 microspheres with different fabrication parameters: 
double emulsion with dichloromethane (DCM) as organic solvent (503), double emulsion with acetonitrile 
(ACN) as organic solvent, and single emulsion (503 DMSO) with DCM as organic solvent. Error bars represent 



































Appendix Figure 11: FITC release from 10mg of 504, 756, and 858 microspheres with different fabrication 
parameters: different molecular weight polymers and single emulsion fabrication for 756 DMSO. Error bars 
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Appendix A.3.4 Material Shelf Stability and Sterilization 
Brimonidine-loaded MS morphology was maintained as spherical and generally non-
porous after gamma irradiation (Appendix Figure 12) and after storage at -20°C, 4°C, and 25°C 




Appendix Figure 12: Scanning electron images of control BT MS (left) and gamma irradiated BT MS (right). 
Scale bar = 10µm. 
 
Gamma irradiation (Appendix Figure 13) of BT microspheres resulted in significant 
decrease in endotoxin concentration from 2.65 ± 1.34 EU/mL to 1.28 ± 0.09 EU/mL. No significant 
difference in endotoxin concentration on gel was observed, with 2.71 ± 0.45 EU/mL on control 
samples and 2.58 ± 0.47 EU/mL on irradiated samples. For a 100µL dose, these values are well 
below the recommended limit of 1 EU/dose [177,181]: 0.265 ± 0.134 EU/dose, 0.128 ± 0.009 
EU/dose, 0.271 ± 0.045 EU/dose, and 0.258 ± 0.047 EU/dose for control MS, irradiated MS, 





Appendix Figure 13: Endotoxin testing of control and gamma irradiated BT microspheres and PNIPAAm 
gel. Significance (*p<0.05) was determined using Mann Whitney U test, with significant decrease in endotoxin 
concentration observed after sterilization of microspheres but not gel. All endotoxin levels are below recommended 
limits. Error bars represent mean ± standard deviation for n=9 samples for gel, n=6 samples for control BT MS, and 
n=3 samples for sterilized BT MS. 
 
No significant morphological changes were observed under SEM for BT MS stored at 
various storage temperatures up to 12 months (Appendix Figure 14). After 12 months of storage, 
there was no difference in the release curves of the MS stored at different temperatures (Appendix 
Figure 15). Initial burst was comparable to original formulation tested immediately after 
fabrication without long term storage. However, slope of the curve was flattened, resulting in 
slightly lower overall magnitude of release although the release magnitude remained in the same 


































Appendix Figure 14: Scanning electron microscopy images of BT MS stored at -20°C, 4°C, and 25°C for 1, 3, 
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Appendix Figure 15: Release curves of BT MS stored at -20°C, 4°C, and 25°C for 12 months compared to 
original formulation. Error bars represent mean ± standard deviation for n=3 samples. 
 
An increase of 1°C in LCST (35.5°C to 36.5°C) was observed for gel stored at 4°C after 6 
and 12 months of storage compared to control gel.  This 1°C increase in LCST was also observed 
for gel stored at 25°C after 3 months but not at 1 or 6 months. Gel stored at 30°C demonstrated a 
1°C decrease in LCST to 34.5°C at 6 months and a 1°C increase in LCST to 36.5°C at 1, 3, and 
12 months of storage. Sterilization also resulted in a 1°C increase in LCST from 35.5°C to 36.5°C. 
Overall, storage at various temperatures for up to 12 months (Appendix Figures 16-18) and gamma 
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Appendix Figure 16: Lower critical solution temperature of pNIPAAm gel at t=0, 6, and 12 months of storage 
at 4°C. A 1°C shift in LCST is observed due to storage for 6 and 12 months compared to control. Error bars 
represent mean ± standard deviation for n=3 samples. 
 
 
Appendix Figure 17: Lower critical solution temperature of pNIPAAm gel for control and t=1, 3, and 6 
months of storage at 25°C. A 1°C shift in LCST is observed due to storage for 3 months compared to control, 1 
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Appendix Figure 18: Lower critical solution temperature of pNIPAAm gel for control and t=1, 3, 6, and 12 
months of storage at 30°C. Error bars represent mean ± standard deviation for n=3 samples. 
 
 
Appendix Figure 19: Lower critical solution temperature of control and sterilized pNIPAAm gel. A 1°C shift 


























































Appendix A.4 Discussion 
The variety of release profiles developed with various fabrication techniques indicate that 
the drug delivery platform can be easily modified to produce desired release duration and 
magnitude. In addition, FITC-loaded MS can be fabricated to produce a variety of release profiles 
to use as a surrogate molecule for experiments such as permeability or distribution studies, 
including BT and ciprofloxacin as shown in these studies and can easily be adapted for other 
therapeutics. Fluorescein use allows for easy visualization with the eye, fluorescent microscopy, 
and/or fluorescence measurement via spectrophotometry and is a cheaper, widely commercially 
available alternative to using active therapeutics, which are factors than can increase ease of 
research into drug delivery systems. 
BT MS have shown to be shelf stable at -20°C, 4C°, and 25°C for up to 12 months of 
storage. These results are consistent with previous studies by other groups [204,205]. In one of 
these studies, a dexamethasone-loaded PLGA MS/PVA gel system experienced increased initial 
burst release and lag phase decreased by half, shortening overall release duration [205]. Because 
the hydrogel and MS were stored together, water content of the hydrogel can cause hydrolysis of 
the PLGA MS. In addition, accelerated physical aging of the PLGA MS occurs at ambient 
temperatures [203,204]. BT MS were stored separately from gel, which may have contributed to 
better shelf stability at 25°C than if MS were stored in gel. While these stability studies indicate 
BT MS and gel can be stored at room temperature, it is still advisable for them to be kept at 4°C 
or below for optimal preservation over a 12-month shelf life. PLGA MS are typically stored at -
20°C but based on both our studies and previous studies by other groups, it would be feasible to 
store both materials at 4°C for ease of storage in one location in patients’ homes. 
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A decrease in overall magnitude of BT release from MS was observed when PVA used in 
fabrication was changed to a new lot. To investigate quality control issues associated with these 
different lots of PVA, several different brands and similar listed molecular weight ranges were 
tested and true molecular weights of PVA brands/lots that resulted in successful BT MS 
formulation were determined using size exclusion chromatography. It was determined that true 
MW was much greater than the listed MW for each of the 3 tested lots (Appendix Table 5). 
Because lots are packaged from a combination of high and low MW PVA and listed MW is an 
average, it is possible that individual packages may have higher or lower average MW than the 
listed average. This PS 2019 lot exhibited two peaks corresponding to 76,000Da and 30,000Da, 
an observation which may support this hypothesis. 
To our knowledge, there have been no previous investigations of PVA molecular weight 
effect on MS formulations. However, a number of studies have investigated the effects on release 
profiles of using different surfactants as stabilizers in MS fabrication [191,192,207,208], effects 
of co-encapsulation of surfactants in MS [209,210], and drug-surfactant interactions [196]. It has 
been previously noted that investigating the underlying molecular interactions between surfactant, 
drug, and PLGA may be difficult but assessing PLGA MS release profiles can provide indirect 
insight into surfactant effect [191,192]. 
Two of the aforementioned studies specifically compared use of PVA to poly(vinyl 
pyrrolidone (PVP) [191,207]. Capan et al reported higher loading efficiency of plasmid DNA into 
MS fabricated using PVA (MW 30,000-70,000Da) compared to PVP (MW 40,000Da) [207]. They 
also observed differences in MS size and loading efficiency due to concentration of PVA used, 
with a 4% solution resulting in highest loading, which affirms the standard use of 4% PVA in MS 
fabrication methods. In contrast, Coombes et al reported lower protein loading, higher initial burst 
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release, and lower overall magnitude of protein release due to use of PVA (MW 13,000-23,000Da) 
compared to PVP (MW 10,000Da) [191]. In this particular study, it was hypothesized that PVP 
better stabilized the primary emulsion, shielding the protein from degradation. Additionally, 
studies on co-encapsulation of surfactants in MS loaded with proteins or insulin demonstrated 
lower encapsulation efficiency and faster overall release [209,210]. These studies hypothesized 
that presence of surfactant can affect the interaction of PLGA and encapsulated therapeutics. 
Similar to how 4% PVA concentration yields optimal loading efficiency (compared to 1% 
and 7% concentrations) [207], it is possible that a narrow range of PVA MW can yield optimal 
release profiles for specific applications. We observed lower overall burst release and magnitude 
of release due to use of PS 2019 and Alfa Aesar PVA compared to the original PS 2015 lot, which 
had an experimentally-determined MW of 66,000Da. Alfa Aesar PVA exhibited a lower 
experimentally-determined MW and PS 2019 exhibited both higher and lower experimentally-
determined MW. In contrast, ciprofloxacin-loaded MS fabricated using these different PVA lots 
did not exhibit a significant difference in release profiles. Therefore, we hypothesize that MW of 
PVA has an effect on MS formulation and that this effect is drug-dependent. 
As previously described, use of different types and MW of surfactants can affect loading 
and release of therapeutics in different ways [191,207–210]. While BT interaction with surfactants 
has not been previously explored, one study examined the effect of drug-surfactant interactions of 
various drugs including timolol, which is also an anti-glaucoma drug [196]. While most surfactants 
tested did not have a significant effect on timolol’s permeability, there was a strong inverse 
correlation with concentration of sodium dodecyl sulfate (SDS) on transport across a dialysis 
membrane. This is likely due to charge interaction of timolol and SDS which at pH 7.4 are, 
respectively, positively and negatively charged.  
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Accordingly, future quality control work can focus on determining optimal molecular 
weight of PVA to produce desired release profiles. Size exclusion chromatography can continue 
to be used to determine true MW of PVA lots and to isolate the MW of interest for use in 
fabrication. Due to a lack of research into molecular interactions between surfactant, drugs, and 
PLGA, these studies may provide more insight into surfactant effect on PLGA MS formulation 
and how to ensure repeatable formulation, which is important for clinical use and 
commercialization. 
Appendix A.5 Conclusions and Future Directions 
To increase commercialization potential of BT-loaded MS and gel for glaucoma treatment, 
quality control experimentation was performed, including investigation of surfactant effect on 
release curves, ability to be sterilized without significant changes to desired material properties, 
and confirmation of shelf-life stability up to 12 months. In addition, a variety of fabrication 
methods were explored for FITC-loaded MS, resulting in a variety of release profiles that can be 
used as a surrogate for release profiles of interest for other therapeutics. This work confirmed that 
a variety of release profiles can be developed by adjusting fabrication methods, which is beneficial 
to expanding the drug delivery platform for a variety of applications, release magnitudes, and 
treatment durations. Future work will be focused on further investigation of surfactant effect on 
MS fabrication, in particular determining optimal PVA molecular weight for reliable, repeatable 
BT MS fabrication and investigating any drug-dependent contribution to this effect. 
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